ORG_CITY: BRONX

ORG_NAME: JAMES J PETERS VA  MEDICAL CENTER

ORG_STATE: NY

PHR: PROJECT NARRATIVE Spinal cord injury (SCI) disrupts the nerves controlling movement, along with those that regulate functions like heart rate and blood pressure (known as the autonomic nervous system, or ANS). Testosterone (T) plays a significant role in brain health and ANS reflex function in non-neurologically impaired men. However, little is known about the relationships between T, nerve function, and ANS dysfunction after SCI. Interestingly, up to 60% of men with SCI exhibit persistently low T concentrations, which may worsen nerve and ANS dysfunction. In uninjured eugonadal people, a single pharmacologic dose of intranasal T has been shown to quickly improve nerve function, but no study has evaluated if T administration alters nerve and ANS function in men with SCI. Herein, we will conduct the first study to assess the relationships between circulating T and motor and ANS function in male Veterans with SCI. We will also conduct a pilot study in a subset of men with SCI and low T, to test how a single dose of intranasal T impacts motor and ANS function in this population.

PI_NAMEs: GOLDSMITH, JACOB ALLEN (contact)

PROJECT_TERMS: Acute;Affect;Albumins;Androgen Receptor;Androgens;Animal Experimentation;Animal Model;Autonomic nervous system;Binding;Biological;Biological Availability;Blood Pressure;Body Composition;Book Chapters;Brain;brain health;cardiometabolism;cardiovascular disorder risk;cardiovascular health;Cardiovascular Physiology;Cardiovascular system;career;career development;Central Nervous System;Cervical;Chronic;Circulation;Clinical Research;cohort;Data;design;Development;Dissociation;Dose;effective therapy;efficacy evaluation;Electric Stimulation;Electromyography;Energy Metabolism;Exhibits;Face;Fatty acid glycerol esters;Feasibility Studies;Fellowship;Fertility;Formulation;Fostering;Functional disorder;Genetic Transcription;Goals;Hand;hands on research;Health;Heart;Heart Rate;High Prevalence;Hour;Human;Hypogonadism;Impaired health;Impairment;improved;Injury;Learning;Literature;Maintenance;male;Measures;Medical center;men;Mentors;Mentorship;Methods;Modification;Motor;motor control;Movement;Muscle;Muscle Weakness;Myelin;Natural regeneration;Nerve;Nervous System Physiology;neural;Neurodegenerative Disorders;Neuronal Plasticity;neurophysiology;Neurophysiology - biologic function;neuroprotection;neuroregulation;Neurostimulation procedures of spinal cord tissue;neurotrophic factor;non-genomic;novel;Output;Persons;pharmacologic;Phase;Physiologic pulse;Physiological;Pilot Projects;Placebos;Play;Population;Postdoctoral Fellow;premature;Publications;Publishing;Quality of life;receptor;recruit;Reflex action;Research;Research Training;response;Risk;Role;Safety;Scientist;Sensorimotor functions;Severities;Sex Hormone-Binding Globulin;Signal Transduction;skills;Spinal Cord;Spinal cord injury;symposium;Symptoms;systemic inflammatory response;Testing;Testosterone;testosterone replacement therapy;Therapeutic;Thinness;Tissues;tool;Transcranial magnetic stimulation;Veterans;Virginia;welfare;Work

PROJECT_TITLE: The Role of Androgens in Neurophysiological and Autonomic Function in Male Veterans with Spinal Cord Injury


ADMINISTERING_IC: DC

ARRA_FUNDED: N

ED_INST_TYPE: SCHOOLS OF MEDICINE

FUNDING_MECHANISM: OTHER RESEARCH-RELATED

IC_NAME: NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS

NIH_SPENDING_CATS: Autoimmune Disease;Basic Behavioral and Social Science;Behavioral and Social Science;Brain Disorders;Multiple Sclerosis;Neurodegenerative;Neurosciences

ORG_CITY: NEW YORK

ORG_COUNTRY: UNITED STATES

ORG_DEPT: OTOLARYNGOLOGY

ORG_FIPS: US

ORG_NAME: NEW YORK UNIVERSITY SCHOOL OF MEDICINE

PHR: PROJECT NARRATIVE The proposed research will elucidate behavioral, cellular, and circuit mechanisms of de- and remyelination and establish a powerful new model to assay drugs that may increase remyelination and functional recovery. There- fore, the proposed research is relevant to public health and part of the NIH’s mission to develop scientific re- sources that will ensure the Nation’s capability to prevent and, one day, cure disease.

PI_NAMEs: AUER, FRANZISKA  (contact)

PROGRAM_OFFICER_NAME: RIVERA-RENTAS, ALBERTO L

PROJECT_TERMS: Acute;Address;Affect;Axon;Behavior;behavior test;Behavioral;Biological Assay;Cell Surface Proteins;Cells;clinically significant;Data;Demyelinating Diseases;Demyelinations;Development;Disease;Ensure;Equilibrium;experimental study;Functional Imaging;genetic approach;Goals;high reward;high risk;Image;Impairment;in vivo;inhibitor;Laboratories;Larva;Lesion;Light;Link;Measurement;Measures;Methods;Microscopy;Mission;Modeling;Molecular;Monitor;Motion;Multiple Sclerosis;multiple sclerosis patient;Myelin;myelination;Nature;neural circuit;Neuroglia;neuronal circuitry;Neurons;Neurophysiology - biologic function;new technology;novel;Oligodendroglia;Optics;Pharmaceutical Preparations;pharmacologic;Pharmacology;Phase;Population;post-doctoral training;Posture;posture instability;prevent;Public Health;Reagent;Recovery;Recovery of Function;Reflex action;remyelination;Research;Resources;response;restoration;Role;Running;Shapes;Technology;Testing;Therapeutic;Time;tool;Training;Transgenic Organisms;United States National Institutes of Health;Vestibular function;vestibular system;Work;Zebrafish

PROJECT_TITLE: How myelin regulates vestibular circuit function and balance behaviors

STUDY_SECTION: CDRC

STUDY_SECTION_NAME: Communication Disorders Review Committee[CDRC]


ADMINISTERING_IC: CA

FUNDING_MECHANISM: NON-SBIR/STTR RPGS

IC_NAME: NATIONAL CANCER INSTITUTE

NIH_SPENDING_CATS: Biotechnology;Cancer;Cancer Genomics;Genetics;Human Genome;Prevention;Skin Cancer

ORG_CITY: LOS ANGELES

ORG_DEPT: INTERNAL MEDICINE/MEDICINE

ORG_NAME: UNIVERSITY OF CALIFORNIA LOS ANGELES

ORG_STATE: CA

PHR: PROJECT NARRATIVE Skin melanoma readily develop resistance to therapies, and targeted therapy is available only to a subset of patients with skin melanoma. We set out to develop and improve targeted therapy for the majority of patients by generating foundational and comprehensive knowledge of therapy resistance mechanisms. We will co-target these resistance mechanisms to develop combination therapies to improve patient survival.

PI_NAMEs: LO, ROGER S (contact);TACKETT, ALAN

PROGRAM_OFFICER_NAME: CHEN, WEIWEI

PROJECT_TERMS: addiction;Atlases;Bioinformatics;Biological Assay;Cells;Chromatin;Classification;Clinical;clinical development;clinically relevant;combinatorial;Combined Modality Therapy;Communities;Coupled;Custom;Cutaneous Melanoma;Data;data dissemination;data integration;data visualization;Databases;Dependence;Development;Disease Progression;disorder subtype;Drug Targeting;Evolution;exome;fitness;genome sequencing;Genomics;Human;Immune Evasion;Immunotherapy;improved;in vivo;inhibitor;inhibitor therapy;interest;Knowledge;Link;Literature;Malignant Neoplasms;MAP Kinase Gene;Maps;Mass Spectrum Analysis;MEKs;Melanoma;Mitogen-Activated Protein Kinase Inhibitor;Molecular;Multiomic Data;multiple omics;mutant;neoplastic cell;NF1 gene;non-genomic;Pathway interactions;patient derived xenograft model;patient subsets;Patients;pharmacologic;Phase;Phenotype;pre-clinical;preclinical trial;prevent;prognostic;programs;proteogenomics;Proteome;Proteomics;public database;Rationalization;Recurrence;Relapse;Residual Neoplasm;Resistance;Resistance development;resistance mechanism;Resources;Safety;Science;support tools;synergism;targeted treatment;Techniques;Testing;The Cancer Genome Atlas;Therapeutic;therapeutic target;therapy resistant;tool;transcriptome;transcriptomics;tumor;United States National Institutes of Health;Validation;Visualization;web portal;whole genome

PROJECT_TITLE: Melanoma Resistance Evolution Atlas (MREA) for identifying combinatorial targets to prevent and reverse MAPKi resistance

STUDY_SECTION: MCTB

STUDY_SECTION_NAME: Mechanisms of Cancer Therapeutics B Study Section[MCTB]


ADMINISTERING_IC: AI

IC_NAME: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

ORG_DEPT: MICROBIOLOGY/IMMUN/VIROLOGY

ORG_NAME: ALBERT EINSTEIN COLLEGE OF MEDICINE

PHR: The PROVIDENT consortium will develop vaccines and treatments against three different fami- lies of viruses that contain many epidemic and pandemic threats. Our goal is to create ap- proaches to vaccination that are generalizable, so that they can be quickly applied to develop a vaccine against a related but distinct outbreak virus.

PI_NAMEs: CHANDRAN, KARTIK  (contact)

PROGRAM_OFFICER_NAME: BRIDWELL, ANNE ELIZABETH MAYER

PROJECT_TERMS: Academia;Achievement;Advanced Development;Animal Model;Animals;Antibodies;Antibody Repertoire;Antibody Response;Antibody-mediated protection;Antigens;Biological;Biological Assay;Bispecific Monoclonal Antibodies;Blood Vessels;Cells;Cellular Immunology;clinical translation;Collaborations;commercialization;Complement;Critical Pathways;data management;design;Development;Disease;Disease Outbreaks;Dissection;Dose;endothelial dysfunction;Engineering;epidemic potential;Evaluation;Event;Exercise;experimental study;Family;Future;Genetic;Genotype;Glycoproteins;Goals;Government;Hantavirus;Human;Immune response;Immunize;immunogenicity;Immunologics;Immunotherapeutic agent;in vivo;Industry;industry partner;Infection;Institution;Integration Host Factors;Knowledge;Lead;Maps;member;Mining;Molecular;Nairovirus;nonhuman primate;Orthobunyavirus;pandemic potential;Paramyxovirus;Pathogenesis;Pathogenicity;Pathway interactions;Phase;Play;Positioning Attribute;prophylactic;protective efficacy;Proteins;Proteomics;prototype;receptor;Recombinants;Research;Research Project Grants;response;Risk Assessment;risk mitigation;RNA;RNA vaccine;RNA Viruses;Safety;safety assessment;Series;Serotyping;structural biology;Structure;Surface Antigens;T cell response;Testing;Therapeutic;Therapeutic antibodies;Therapeutic Uses;tool;Toxin;Transgenic Animals;Vaccination;Vaccine Design;vaccine development;vaccine platform;vaccine strategy;vaccine-induced antibodies;Vaccines;Validation;Viral;Viral Pathogenesis;virology;Virus;Virus Diseases;virus host interaction;virus infection mechanism

PROJECT_TITLE: PROVIDENT:  Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics against Diverse Emerging Infectious Threats

STUDY_SECTION_NAME: Special Emphasis Panel[ZAI1 FDS-M (J1)]


NIH_SPENDING_CATS: Biodefense and Related Countermeasures;Biotechnology;Emerging Infectious Diseases;Immunization;Immunotherapy;Infectious Diseases;Orphan Drug;Prevention;Rare Diseases;Vaccine Related

PHR: Please see Overall for Project Narrative.

PROJECT_TERMS: Advanced Development;Agreement;Animal Welfare;Animals;Architecture;arm;Collaborations;college;commercialization;Communication;Communities;Conflict (Psychology);Constitution;Data;data management;data sharing;Development;Disease Outbreaks;Fostering;Goals;Hantavirus;Human Resources;human subject;Immunotherapeutic agent;industry partner;Intellectual Property;Maintenance;Medicine;meetings;member;Mission;Monitor;Nairovirus;National Institute of Allergy and Infectious Disease;Occupational activity of managing finances;Office of Administrative Management;Paramyxovirus;Play;Positioning Attribute;Process;programs;Progress Reports;Publications;Reagent;Report (document);Reporting;Research;Research Project Grants;Resolution;Resource Sharing;Resources;Risk;Risk Management;RNA Viruses;Role;Shipping;Site Visit;Therapeutic antibodies;Travel;vaccine strategy;vaccine-induced antibodies;web site

PROJECT_TITLE: CORE A:  Administrative Core


NIH_SPENDING_CATS: Biotechnology;Data Science;Emerging Infectious Diseases;Immunization;Immunotherapy;Infectious Diseases;Networking and Information Technology R&D (NITRD);Prevention;Vaccine Related

PI_NAMEs: MITTLER, EVA-MARIA  (contact)

PROJECT_TERMS: Adopted;Agreement;Animal Model;Basic Science;Biochemical;Biological;Center for Translational Science Activities;cloud based;Collaborations;Colorado;Complex;Coordination and Collaboration;Data;data exchange;data harmonization;data lake;data management;data quality;data repository;data resource;Data Science;Data Security;data sharing;data standards;Data Storage and Retrieval;data structure;data submission;Database Management Systems;Development;encryption;Ensure;FAIR principles;flexibility;Fostering;Foundations;Future;Goals;Guidelines;Hantavirus;Housing;Immunotherapeutic agent;Information Technology;Infrastructure;Institution;Intellectual Property;Interdisciplinary Study;Knowledge;Lead;Maintenance;member;Monoclonal Antibodies;Multiomic Data;Nairovirus;National Institute of Allergy and Infectious Disease;novel;open data;open-access repositories;pandemic preparedness;Paramyxovirus;Periodicals;Play;Policies;Positioning Attribute;Process;programs;Protocols documentation;Reagent;relational database;repository;Reproducibility;Research;research and development;Research Project Grants;resilience;Resource Sharing;Resources;Role;Secure;Standardization;Strategic Planning;Structure;synergism;timeline;United States National Institutes of Health;Universities;vaccine strategy;vaccine-induced antibodies

PROJECT_TITLE: CORE B:  Data Management Core


PI_NAMEs: MCLELLAN, JASON SCOTT (contact)

PROJECT_TERMS: 2019-nCoV;Address;Antibodies;Antigens;assay development;Automation;Binding;biophysical properties;Bispecific Monoclonal Antibodies;Bunyavirales;Cell Line;Cell membrane;Chimeric Proteins;Collection;Complex;Cryoelectron Microscopy;Crystallization;Data;Data Set;design;design and construction;detector;Development;Diagnostic;Drops;Electron Microscope;Electrons;Engineering;Epitopes;experience;experimental study;Family;Formulation;Foundations;Glycoproteins;high throughput screening;Image;Immune response;Immune system;Immunization;immunogenicity;Immunoglobulin Fragments;Immunologic Stimulation;Immunotherapeutic agent;insight;instrument;Interferometry;Intervention;Knowledge;Laboratories;Lead;Leadership;Libraries;light scattering;Location;Mammalian Cell;Mediating;meetings;Membrane Glycoproteins;Membrane Proteins;Methodist Church;Molecular Conformation;molecular dynamics;Molecular Machines;Molecular Sieve Chromatography;Molecular Structure;Negative Staining;neutralizing antibody;pandemic preparedness;Paramyxovirus;particle;pathogen;pathogenic virus;Plasmids;Play;Positioning Attribute;Process;Production;Protein Engineering;protein expression;protein purification;protein structure;Proteins;prototype;rational design;Reagent;receptor;Receptor Cell;Research Project Grants;Research Support;Resolution;Respiratory Syncytial Virus Vaccines;RNA Viruses;Role;Sampling;Scanning;screening;Services;Specific qualifier value;Standardization;stoichiometry;structural biology;Structure;Surface Plasmon Resonance;synthetic biology;Technology;Testing;Therapeutic antibodies;thermostability;tool;Vaccine Antigen;Vaccine Design;vaccine development;vaccine strategy;vaccine-induced antibodies;Vaccines;Variant;Viral;Viral Physiology;Viral Proteins;virology;Virus;Work;X-Ray Crystallography

PROJECT_TITLE: CORE C:  Structure & Protein Engineering Core


NIH_SPENDING_CATS: Biodefense and Related Countermeasures;Bioengineering;Biotechnology;Emerging Infectious Diseases;Immunization;Immunotherapy;Infectious Diseases;Orphan Drug;Prevention;Rare Diseases;Tickborne Diseases;Vaccine Related;Vector-Borne Diseases

PI_NAMEs: COHEN, COURTNEY  (contact)

PROJECT_TERMS: adaptive immunity;Alpaca;Andes Virus;Animal Model;animal model development;Animals;Antibodies;Antigens;Blood Vessels;candidate selection;Cell Culture Techniques;Collaborations;Communication;Crimean-Congo Hemorrhagic Fever Virus;CRISPR/Cas technology;Data;Development;diagnostic tool;Disease;disease model;Disease Outbreaks;Dose;efficacy study;efficacy testing;Engineering;Ensure;Evaluation;Family;Foundations;Generations;genome editing;Glycoproteins;Goals;Hamsters;Hantaan virus;Hantavirus;Immunization;Immunize;immunogenicity;Immunotherapeutic agent;In Vitro;in vitro testing;in vivo;in vivo evaluation;Infection;Integration Host Factors;Iowa;Lead;lead candidate;Measurement;medical countermeasure;member;Mesocricetus auratus;Modeling;Monoclonal Antibodies;Mus;Nairovirus;nanobodies;Nipah;Nipah Virus;nonhuman primate;novel;novel vaccines;Paramyxovirus;pathogen;Pathogenesis;phase I trial;Play;Positioning Attribute;pre-clinical;Preclinical Testing;Predisposition;protective efficacy;Proteins;prototype;rapid testing;Recombinants;Research Project Grants;RNA;RNA vaccine;RNA Viruses;Rodent;Rodent Model;Role;Sampling;Services;Sin Nombre virus;Stress Tests;Surface;Testing;Therapeutic;Therapeutic antibodies;Time;tool;Transgenic Animals;Universities;Update;Utah;vaccine candidate;vaccine strategy;vaccine-induced antibodies;Vaccines;Validation;Viral;Viral Pathogenesis;Viral Proteins;Virus;virus development;virus host interaction;Virus Replication

PROJECT_TITLE: CORE D:  Animal Models and In Vivo Evaluation Core


PI_NAMEs: COOKE, JOHN P (contact)

PROJECT_TERMS: Antigens;Artificial Intelligence;Biological Assay;Cells;Client;Clinic;Clinical;clinical translation;Codon Nucleotides;Collaborations;COVID-19 pandemic;COVID-19 vaccine;Cyclic GMP;design;design and construction;Development;Discipline;Drug Design;Effectiveness;Emergency Situation;Encapsulated;Engineering;Ensure;experience;Freeze Drying;Gene Expression;Genes;genetic immunization strategies;Genome;Goals;Hospitals;Immune response;Immune system;immunogenicity;Immunotherapeutic agent;improved;in vivo;innovation;insight;Lead;Leadership;lipid nanoparticle;Lipids;manufacture;Messenger RNA;Methodist Church;Modification;Molecular;Mutation;novel;Nuclear;Nucleosides;Other Genetics;pathogen;Population;Positioning Attribute;preclinical study;Preclinical Testing;Procedures;Process;Production;Proliferating;Protein Engineering;Replicon;Research;research and development;Research Project Grants;Risk;RNA;RNA vaccine;Safety;Scientist;screening;Services;Specificity;Structure;Technology;Therapeutic;therapeutic RNA;timeline;tool development;vaccine candidate;vaccine platform;vaccine strategy;Vaccinee;Vaccines;Validation;virology;Virus;Work

PROJECT_TITLE: CORE E: RNA Manufacturing Core


NIH_SPENDING_CATS: Biodefense and Related Countermeasures;Bioengineering;Biotechnology;Clinical Research;Emerging Infectious Diseases;Genetics;Immunization;Immunotherapy;Infectious Diseases;Prevention;Tickborne Diseases;Vaccine Related;Vector-Borne Diseases

PROJECT_TERMS: Alpaca;Andes Virus;Animal Model;animal model development;Animals;Antibodies;Antigens;Biological;Biological Assay;biomarker identification;Blood Vessels;candidate validation;Cell surface;Cells;Co-Immunoprecipitations;Collaborations;Crimean-Congo Hemorrhagic Fever Virus;CRISPR/Cas technology;Critical Pathways;Data;design;Development;Dissection;emerging virus;endothelial dysfunction;Endothelium;Engineering;Epithelium;Family;Flavivirus;Foundations;Functional disorder;Genes;Genetic;genetic approach;Genetic Processes;Genetic Screening;Glycoproteins;Goals;Hantavirus;Hantavirus Infections;Hemorrhage;Homeostasis;Human;human monoclonal antibodies;Immune Sera;Immunize;Immunotherapeutic agent;In Vitro;in vivo;in vivo Model;Infection;Integration Host Factors;Interdisciplinary Study;Investigation;Knowledge;Life Cycle Stages;Mammalian Cell;Maps;Mass Spectrum Analysis;Mediating;medical countermeasure;member;Mesocricetus auratus;Modeling;Molecular;Monoclonal Antibodies;Mus;Mutagenesis;Nairovirus;novel;pandemic preparedness;Paramyxovirus;Pathogenesis;Pathogenicity;Pathologic;Pathology;Pathway interactions;Permeability;Phase;phosphoproteomics;Polysaccharides;Positioning Attribute;prevent;Primary Cell Cultures;Production;protein complex;Proteins;Proteomics;prototype;Reagent;receptor;Recombinants;Research Project Grants;Rodent Model;Role;Sampling;SARS-CoV-2 spike protein;screening;Serum;Services;Severity of illness;Surface;Testing;Therapeutic;Time;Toxin;Transgenic Animals;Vaccinated;vaccine evaluation;vaccine immunogenicity;vaccine strategy;Vaccines;Validation;Vesicular stomatitis Indiana virus;Viral;Viral Pathogenesis;Viral Proteins;Virion;virology;Virulence;Virus;Virus Diseases;virus host interaction;virus infection mechanism

PROJECT_TITLE: Research Project 1: Discovery and dissection of virus-host interactions and pathogenetic mechanisms


NIH_SPENDING_CATS: Biodefense and Related Countermeasures;Bioengineering;Biotechnology;Emerging Infectious Diseases;Immunization;Immunotherapy;Infectious Diseases;Orphan Drug;Prevention;Rare Diseases;Vaccine Related;Vector-Borne Diseases

PI_NAMEs: BRADFUTE, STEVEN  (contact)

PROJECT_TERMS: Amino Acids;Andes Virus;animal efficacy;Animal Model;Animals;Antibody Binding Sites;Antibody Repertoire;Antibody Response;Antibody Specificity;Antigens;B-cell receptor repertoire sequencing;B-Lymphocyte Subsets;B-Lymphocytes;Binding;Biological Assay;Cell Physiology;Cells;Cellular Immunity;comparative;Complex;Crimean-Congo Hemorrhagic Fever Virus;Crystallography;cytokine;Cytotoxic T-Lymphocytes;design;Distant;efficacy study;efficacy testing;Engineering;Environment;Enzyme-Linked Immunosorbent Assay;Epitopes;Evaluation;experience;Family;Goals;Hantaan virus;Hantavirus;Head;Helper-Inducer T-Lymphocyte;Humoral Immunities;Immune;Immune response;immunogenicity;Immunologics;Immunotherapeutic agent;in vivo;Investigation;Knowledge;Lead;lead candidate;Machine Learning;Maps;Mediating;Membrane Proteins;Methodology;Monoclonal Antibodies;multiple myeloma M Protein;Mus;Nairovirus;Nipah Virus;novel;Orthobunyavirus;pandemic potential;Paramyxovirus;pathogenic virus;Peptides;Peripheral;polyclonal antibody;Positioning Attribute;Process;Production;protective efficacy;protein complex;Protein Engineering;Proteins;prototype;Recombinants;Reference Standards;Research Project Grants;Resources;RNA vaccine;Role;Sampling;Sin Nombre virus;Splenocyte;structural biology;Structure;Surface;Surface Antigens;T cell receptor repertoire sequencing;T cell response;T memory cell;T-Cell Depletion;T-cell diversity;T-Lymphocyte;T-Lymphocyte Subsets;tissue resident memory T cell;Tissues;Up-Regulation;Vaccinated;Vaccination;Vaccine Antigen;Vaccine Design;vaccine development;vaccine efficacy;vaccine platform;vaccine strategy;Vaccines;Viral;Viral Antigens;Viral Vaccines;Virus;Virus Diseases;Work

PROJECT_TITLE: Research Project 2:  Antigen design and immunological evaluation


NIH_SPENDING_CATS: Biodefense and Related Countermeasures;Biotechnology;Coronaviruses;Coronaviruses Vaccines;Emerging Infectious Diseases;Immunization;Immunotherapy;Infectious Diseases;Prevention;Vaccine Related

PI_NAMEs: ERASMUS, JESSE HONG-SAE (contact)

PROJECT_TERMS: 2019-nCoV;Achievement;Address;Adverse reactions;Animal Model;Antibodies;Antibody Response;Antigen Targeting;Antigens;Cell membrane;Cell surface;Characteristics;COVID-19;COVID-19 pandemic;COVID-19 vaccine;Cytoplasm;design;Development;Dose;Emerging Communicable Diseases;Equilibrium;Extracellular Space;Family;Family member;Formulation;Future;future pandemic;Generations;Glycoproteins;Hantavirus;Human;Immune;Immune response;Immune system;Immune Targeting;immunogenicity;Immunologic Memory;Immunotherapeutic agent;improved;In Situ;Infection;Innate Immune Response;insight;Knowledge;Lead;Licensing;Link;Maps;Messenger RNA;Methodology;Methods;Middle East Respiratory Syndrome Coronavirus;Modality;multidisciplinary;Nairovirus;neutralizing antibody;next generation;novel;Nucleotides;Orthobunyavirus;Outcome;pandemic disease;pandemic potential;Paramyxovirus;particle;pathogen;Pathogenicity;Positioning Attribute;Process;Production;Proteins;prototype;Public Health;Replicon;Research;Research Project Grants;response;RNA;RNA replication;RNA vaccination;RNA vaccine;Safety;Structural Protein;Structure;subcellular targeting;T cell response;Technology;Testing;timeline;Toxin;Vaccine Antigen;vaccine candidate;vaccine development;vaccine efficacy;vaccine platform;vaccine strategy;Vaccines;Variant;Viral;Viral Proteins;Virus;Virus-like particle

PROJECT_TITLE: Research  Project 3: Rapid-Response Roadmap for RNA vaccines


NIH_SPENDING_CATS: Biodefense and Related Countermeasures;Bioengineering;Biotechnology;Clinical Research;Emerging Infectious Diseases;Immunization;Immunotherapy;Infectious Diseases;Machine Learning and Artificial Intelligence;Orphan Drug;Prevention;Rare Diseases;Tickborne Diseases;Vaccine Related;Vector-Borne Diseases

PI_NAMEs: GOLLIHAR, JIMMY D (contact)

PROJECT_TERMS: Address;Advanced Development;Aerosols;Affinity;Algorithm Design;Algorithms;Andes Virus;Animal Model;Animals;Antibodies;antibody engineering;Antibody Repertoire;Antibody Response;Antibody Therapy;Antigen-Antibody Complex;Antigens;Area;B cell repertoire;B-cell receptor repertoire sequencing;B-Lymphocyte Subsets;B-Lymphocytes;Base Sequence;Biological;Biological Assay;Bispecific Monoclonal Antibodies;Bite;Catalogs;Cell Culture Techniques;Cell Line;Cell Separation;cellular engineering;Clinical;Collection;combat;Crimean-Congo Hemorrhagic Fever Virus;cross reactivity;Cryoelectron Microscopy;Culicidae;Data;design;Development;Disease;Disease Progression;Disparate;emerging virus;Encephalitis;Engineering;Epitope Mapping;Epitopes;Evaluation;Evolution;experience;experimental study;Family;forward genetics;Future;future outbreak;Generations;Goals;Hantaan virus;Hantavirus;Hemorrhage;holistic approach;Human;human monoclonal antibodies;Humoral Immunities;Immune;Immune response;Immunity;Immunoglobulins;Immunology;Immunotherapeutic agent;improved;in vivo;in vivo evaluation;Individual;Infection;inhibiting antibody;insight;lead candidate;Machine Learning;machine learning algorithm;Maintenance;Mammalian Cell;manufacturability;manufacture;Maps;Memory B-Lymphocyte;Methodology;Mining;Modality;Modeling;Molecular;Monoclonal Antibodies;Morbidity - disease rate;mortality;Mutation;mutation screening;Nairovirus;neutralizing antibody;neutralizing monoclonal antibodies;Nipah Virus;novel;novel therapeutics;novel vaccines;Paramyxovirus;Peripheral;Phlebotominae;Plasma;Play;Population;Positioning Attribute;Production;prophylactic;Protein Engineering;Proteomics;Public Health;Reagent;Research;Research Project Grants;Respiratory Disease;Scientist;Serology;Serum;Sin Nombre virus;stable cell line;Stress Tests;Structure;Structure-Activity Relationship;Surface;Syndrome;Techniques;Technology;Therapeutic;Ticks;Time;tool;Training;transmission process;vaccine candidate;Vaccine Design;vaccine strategy;Vaccines;vaccinology;Validation;Vesicular stomatitis Indiana virus;Viral;virology;Virus;virus host interaction;Virus Receptors;Visualization;Work

PROJECT_TITLE: Research Project 4:  Mining human antibody responses to inform vaccine and therapeutic design


ADMINISTERING_IC: GM

ED_INST_TYPE: SCH ALLIED HEALTH PROFESSIONS

FUNDING_MECHANISM: TRAINING, INSTITUTIONAL

IC_NAME: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

ORG_CITY: UNIVERSITY PARK

ORG_DEPT: MISCELLANEOUS

ORG_NAME: PENNSYLVANIA STATE UNIVERSITY, THE

ORG_STATE: PA

PHR: PROJECT NARRATIVE The role of stress as the underlying cause for human adaptation is well-appreciated. Inherent in this response is the logical progression to human disease and disability, as there is little debate regarding the link between many different types of stress and the natural history of disease initiation and progression. The proposed program will focus on predoctoral scientist training in common themes of stress adaptation, and emphasize new core competencies that will develop new research skill sets, preparing scientists to innovate and discover novel therapeutic interventions.

PI_NAMEs: CANTORNA, MARGHERITA T;HARVATINE, KEVIN JOHN;KORZICK, DONNA HOPE (contact)

PROGRAM_OFFICER_NAME: STEPANEK, LAURIE ELIZABETH

PROJECT_TITLE: Research Training in Physiological Adaptations to Stress

STUDY_SECTION: TWD

STUDY_SECTION_NAME: Training and Workforce Development Study Section - B[TWD-B]


ADMINISTERING_IC: HL

IC_NAME: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

NIH_SPENDING_CATS: Cardiovascular;Clinical Research;Clinical Trials and Supportive Activities;Heart Disease

ORG_CITY: DURHAM

ORG_NAME: DUKE UNIVERSITY

ORG_STATE: NC

PHR: Narrative The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction Extension Study (SPIRRIT-EX) is an extension of the SPIRRIT-HFpEF clinical trial that proposes to evaluate the effectiveness of spironolactone versus usual care. The primary hypothesis is that use of spironolactone will have an 18% lower incidence rate of total heart failure hospitalizations or cardiovascular death compared to usual care.

PI_NAMEs: DEVORE, ADAM D (contact)

PROGRAM_OFFICER_NAME: WONG, RENEE P

PROJECT_TERMS: Address;Adherence;adjudication;Adult;Aging;American;Americas;antagonist;Blinded;Cardiovascular Diseases;Cardiovascular system;Cessation of life;Clinical;Clinical Research;clinical trial participant;Clinical Trials;clinically relevant;Country;Data Analyses;Data Coordinating Center;data registry;Data Sources;design;Diagnosis;effectiveness evaluation;EFRAC;Elements;Enrollment;Ensure;Event;evidence base;experience;follow-up;Funding;Future;Guidelines;Heart Arrest;Heart failure;heart failure with reduced ejection fraction;Hospitalization;improved;Incidence;Information Dissemination;Intervention Trial;Lead;Left Ventricular Ejection Fraction;Medical;Meta-Analysis;Methodology;Mineralocorticoid Receptor;Morbidity - disease rate;mortality;North America;Outcome;Participant;participant enrollment;Patients;Pharmaceutical Preparations;Placebos;Population;Pragmatic clinical trial;pragmatic trial;preservation;Prevalence;primary endpoint;primary outcome;Public Health;Randomized;randomized trial;randomized, clinical trials;Registries;Research;Research Institute;Research Personnel;Russia;secondary analysis;secondary endpoint;secondary outcome;South America;Specific qualifier value;Spironolactone;Sweden;symptomatic improvement;Telephone;Testing;Therapeutic;Therapeutic Intervention;Time;treatment as usual;trial enrollment;United States

PROJECT_TITLE: 1/2 Clinical Coordinating Center for the Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction Study (SPIRRIT-EX)

STUDY_SECTION_NAME: Special Emphasis Panel[ZHL1 CSR-Z (J1)]


ADMINISTERING_IC: DK

IC_NAME: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES

NIH_SPENDING_CATS: Bioengineering;Biotechnology;Diabetes;Gene Therapy;Genetics;Nanotechnology;Regenerative Medicine;Wound Healing and Care

ORG_CITY: BOSTON

ORG_NAME: BETH ISRAEL DEACONESS MEDICAL CENTER

ORG_STATE: MA

PHR: PROJECT NARRATIVE Non-healing diabetic foot ulcers affect millions of Americans annually and existing therapeutic interventions are not efficient. This application will investigate how lipid nanoparticles loaded with pro-healing gene encoding mRNAs, and surface-functionalized to target specific cell types, can be delivered with novel biomaterials to accelerate diabetic wound healing. Additionally, using multi-omics approaches, the spatial cellular transcriptomic and proteomic landscape of the wounds will be mapped to determine the exact mechanisms of action.

PI_NAMEs: THEOCHARIDIS, GEORGIOS  (contact)

PROGRAM_OFFICER_NAME: LI, YAN

PROJECT_TERMS: Acceleration;Acute;Advanced Development;Affect;Alginates;American;Amputation;Antibodies;antibody conjugate;Award;Bandage;Biocompatible Materials;Biodistribution;career development;Cell Physiology;cell type;Cells;CHI3L1 gene;Chronic;clinically relevant;comparative;Data;Data Set;db/db mouse;design;Development;diabetes management;Diabetes Mellitus;diabetic;Diabetic Foot Ulcer;Diabetic mouse;diabetic wound healing;Disease;Dose;Dyes;Encapsulated;Endowment;Engraftment;Fibroblasts;Functional disorder;Genes;Growth Factor;healing;HIF1A gene;Human;Hydrogel Bandage;Hydrogels;IL6 gene;Immune;Impairment;improved;In Vitro;in vitro Assay;in vivo;Individual;Inflammation;Inflammatory;Injury;innovation;insight;Interleukin-2;Interstitial Collagenase;Intervention;Investigation;Knowledge;lipid nanoparticle;Lower Extremity;Macrophage;Maps;Mediating;Mentors;Messenger RNA;MMP11 gene;MMP3 gene;Molecular;Molecular Biology Techniques;mouse model;mRNA delivery;multidisciplinary;multiple omics;Names;novel;Operative Surgical Procedures;Outcome;overexpression;particle;Pathway Analysis;Pathway interactions;Patients;Phase;Physiological;Population;Principal Investigator;protein expression;Proteins;proteogenomics;Proteomics;Quality of life;receptor;Reporter Genes;Research;Research Personnel;Series;Shapes;Signal Transduction;single-cell RNA sequencing;Site;Skin;skin wound;Specificity;stromelysin 3;Surface;System;targeted treatment;Therapeutic;Therapeutic Intervention;therapeutic RNA;Time;Tissues;Topical application;transcriptomics;Translation Process;translational potential;Treatment Factor;Ulcer;uptake;Work;wound;wound closure;wound healing;wound treatment

PROJECT_TITLE: Targeted mRNA Delivery to Improve Diabetic Wound Healing

STUDY_SECTION: DDK

STUDY_SECTION_NAME: Diabetes, Endocrinology and Metabolic Diseases B Study Section[DDK-B]


NIH_SPENDING_CATS: Chronic Obstructive Pulmonary Disease;Clinical Research;Emphysema;Genetics;Human Genome;Lung;Precision Medicine;Tobacco;Tobacco Smoke and Health

ORG_CITY: CLEVELAND

ORG_NAME: CLEVELAND CLINIC LERNER COM-CWRU

ORG_STATE: OH

PHR: Project Narrative Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide and a highly variable disease with limited therapies, in part given prior studies do not account for disease heterogeneity with differential therapeutic responses. An understudied and highly prevalent potential phenotype is the heterozygous state of the SERPINA1 gene (encodes for alpha-1 antitrypsin protein) with one wild-type allele (M) and one Z variant allele (rs28929474), known as PI*MZ. We propose studying airway inflammatory and genotypic contributions to disease development among PI*MZ individuals to identify biologic correlates of disease severity and potential treatment targets for a highly prevalent disease phenotype.

PI_NAMEs: TEJWANI, VICKRAM  (contact)

PROGRAM_OFFICER_NAME: LIU, QIAN

PROJECT_TERMS: Acceleration;Address;Affect;airway inflammation;Alleles;alpha 1-Antitrypsin;alpha 1-Antitrypsin Deficiency;Alveolar;authority;Award;Biological;Biological Markers;burden of illness;career;Career Choice;Cause of Death;Chemotactic Factors;chest computed tomography;Chronic Obstructive Pulmonary Disease;Clinic;cohort;Data;Data Set;Development;Disease;disease heterogeneity;disease phenotype;disorder risk;early experience;epidemiology study;experience;Extracellular Matrix;follow-up;Forced expiratory volume function;former smoker;gene environment interaction;gene interaction;Genes;genetic risk factor;Genetic Transcription;genetic variant;Genetic Variation;genome sequencing;genomic data;Genomics;Genotype;Goals;Grant;Heterozygote;IL8 gene;inclusion criteria;Individual;Inflammatory;innovation;Institution;Interleukin-8;K-Series Research Career Programs;Leukocyte Elastase;Leukotriene B4;Leukotrienes;Longitudinal cohort;Lung Diseases;lung injury;Measures;Mentors;Mentorship;Molecular;Morbidity - disease rate;mortality;Multicenter Studies;multidisciplinary;multiple omics;neutrophil;Neutrophil Infiltration;novel;Other Genetics;Outcome;Outcome Measure;Participant;participant enrollment;Pathogenesis;Pathogenicity;Pathway interactions;Phenotype;Precision therapeutics;Preparation;Prevalence;primary outcome;Production;prospective;Protease Inhibitor;protein expression;Proteins;Publishing;Pulmonary Emphysema;pulmonary function;pulmonary function decline;Pulmonary Function Test/Forced Expiratory Volume 1;Quality of life;recruit;Research;Research Personnel;Resources;Respiratory Disease;respiratory health;Risk;Role;secondary outcome;Severities;Severity of illness;skills;small airways disease;Smoker;Smoking History;Sputum;Structure;Symptoms;Techniques;Testing;therapeutic target;Time;Tobacco smoke;Training;Trans-Omics for Precision Medicine;Translational Research;translational scientist;treatment response;Variant;whole genome;X-Ray Computed Tomography;X-Ray Tomography;Zein

PROJECT_TITLE: Leukotriene B4 and IL-8 in alpha-1 heterozygotes (PI*MZ genotype)

STUDY_SECTION: MPOR

STUDY_SECTION_NAME: NHLBI Mentored Patient-Oriented Research Study Section[MPOR (JA)]


ADMINISTERING_IC: NS

ED_INST_TYPE: SCHOOLS OF ARTS AND SCIENCES

FUNDING_MECHANISM: TRAINING, INDIVIDUAL

IC_NAME: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

NIH_SPENDING_CATS: Acquired Cognitive Impairment;Brain Disorders;Dementia;Genetics;Huntington's Disease;Neurodegenerative;Neurosciences;Orphan Drug;Rare Diseases;Stem Cell Research;Stem Cell Research - Embryonic - Non-Human;Stem Cell Research - Induced Pluripotent Stem Cell;Stem Cell Research - Induced Pluripotent Stem Cell - Human

ORG_CITY: IRVINE

ORG_DEPT: OTHER BASIC SCIENCES

ORG_NAME: UNIVERSITY OF CALIFORNIA-IRVINE

PHR: Project Narrative/ Relevance Huntington’s Disease (HD) is a devasting terminal disease with no disease modifying treatments. DNA damage accumulates in HD patients, contributing to neuronal death. The goal of this project is to identify key protein interactions and post translational modifications of DNA damage repair proteins which can be modulated to improve HD phenotypes.

PI_NAMEs: PENDLEBURY, DEVON  (contact)

PROGRAM_OFFICER_NAME: KIM, JENNY LILY

PROJECT_TERMS: Affect;Age of Onset;Amyotrophic Lateral Sclerosis;Atrophic;autosome;Behavior;Binding;Biochemical;Biological Assay;Brain;Brain Diseases;CAG repeat;Cell Nucleus;Cells;Clinical Trials;Clustered Regularly Interspaced Short Palindromic Repeats;Co-Immunoprecipitations;Collaborations;combat;Complex;Corpus striatum structure;Coupled;Cytoplasm;Cytosol;Data;design;Disease;disease model;Disease Outcome;disease phenotype;Disease Progression;DNA;DNA Damage;DNA Double Strand Break;DNA Repair;DNA-dependent protein kinase;Exclusion;experimental study;Genes;Genetic Transcription;genetic variant;Genome;genome integrity;genome wide association study;Goals;Huntington Disease;Huntington gene;improved;improved outcome;In Vitro;in vivo;induced pluripotent stem cell;Induced pluripotent stem cell derived neurons;Inherited;inhibitor;isopeptidase;knock-down;Learning;Ligase;Maintenance;Mediating;Modeling;Modification;Molecular;Motor;mouse model;mutant;Mutation;Nervous System Disorder;neuron loss;neuronal survival;Neurons;neuropathology;new therapeutic target;Nonhomologous DNA End Joining;novel therapeutics;Nuclear;Pathogenesis;Pathology;Patients;Phosphoric Monoester Hydrolases;Phosphorylation;Polynucleotide 5'-Hydroxyl-Kinase;Post-Translational Protein Processing;Pre-Clinical Model;preservation;Process;Protein Phosphatase Inhibitor;protein protein interaction;protein TDP-43;Proteins;recruit;Repair Complex;repair function;repaired;Reporting;Role;STAT1 gene;Structure;SUMO1 gene;Sumoylation Pathway;symptomatic improvement;Symptoms;Terminal Disease;Therapeutic;therapeutic target;tool;Transcription-Coupled Repair;ubiquitin-protein ligase

PROJECT_TITLE: Dissecting Key Interactions of the HTT Transcription Coupled Repair Complex

STUDY_SECTION: NST

STUDY_SECTION_NAME: NST-4 Study Section [NST-4]


NIH_SPENDING_CATS: Cardiovascular;Clinical Research;Heart Disease;Rare Diseases;Stem Cell Research;Stem Cell Research - Induced Pluripotent Stem Cell;Stem Cell Research - Induced Pluripotent Stem Cell - Human

ORG_CITY: BALTIMORE

ORG_NAME: JOHNS HOPKINS UNIVERSITY

ORG_STATE: MD

PHR: Project narrative The heart and skeletal muscle contract when myosin protein pulls on actin filaments and mutations in these and associated proteins can lead to dilated cardiomyopathy through different mechanisms. This study will use methods from single atoms to whole hearts to explore a unique mutation in an actin protein that normally causes skeletal muscle disease but, in this case, causes cardiomyopathy. The findings from this study will establish a new way to study actin proteins in cardiomyopathy and lay the foundation for new heart failure therapies.

PI_NAMEs: GARG, ANKIT  (contact)

PROGRAM_OFFICER_NAME: NEILSON, KAREN MARY

PROJECT_TERMS: ACTA1 gene;Actin-Binding Protein;Actins;Actomyosin;Animal Model;Animals;Biochemical;Biochemistry;Biophysics;Calcium;Cardiac;Cardiac Myocytes;cardiac tissue engineering;Cardiomyopathies;career development;Cell model;Clinical;cohort;Communities;Complex;Contracts;Cryoelectron Microscopy;Data;Development Plans;Dilated Cardiomyopathy;Disease;disease model;Dominant-Negative Mutation;Education;Educational Curriculum;Educational process of instructing;Engineering;Filament;Foundations;Functional disorder;Future;Heart;Heart failure;Heart Transplantation;Human;human induced pluripotent stem cells;improved;In Vitro;in vivo;Induced Cardiomyocytes;induced pluripotent stem cell derived cardiomyocytes;Inherited;Knock-in Mouse;Knowledge;Link;Measures;member;Mentors;Mentorship;Methods;Microfilaments;Minor;Modeling;Molecular;molecular dynamics;mortality;Motility;Mus;Muscle;Muscle Cells;Muscle Contraction;Muscle Fibers;mutant;Mutation;Myocardial dysfunction;Myocardium;Myopathy;Myosin ATPase;novel;optimal treatments;Outcome;Patients;Permeability;Physicians;Physiology;Positioning Attribute;Principal Investigator;Production;Productivity;programs;Protein Dynamics;Protein Isoforms;Proteins;Recombinants;Research;Research Personnel;Resolution;Role;Sarcomeres;Scientist;simulation;skeletal;Skeletal Muscle;skills;stem cells;Structure;System;Techniques;Testing;Time;Tissue Engineering;Tissues;tool;Training;Treatment Failure;Tropomyosin;Troponin

PROJECT_TITLE: Multi-scale Analysis of the Role of Skeletal Muscle Actin Mutations in Dilated Cardiomyopathy

STUDY_SECTION: MCBS

STUDY_SECTION_NAME: NHLBI Mentored Clinical and Basic Science Study Section[MCBS (JA)]


ORG_DEPT: BIOSTATISTICS & OTHER MATH SCI

PHR: Narrative The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction Extension Study (SPIRRIT-EX) is an extension of the SPIRRIT-HFpEF clinical trial that proposes to evaluate the effectiveness of spironolactone versus usual care. The primary hypothesis is that use of spironolactone will result in a lower incidence rate of total heart failure hospitalizations or cardiovascular death compared to usual care.

PI_NAMEs: ANSTROM, KEVIN J;CHAKRABORTY, HRISHIKESH  (contact)

PROJECT_TERMS: Address;Adherence;adjudication;Adult;Aging;American;Americas;antagonist;Blinded;Cardiovascular Diseases;Cardiovascular system;Cessation of life;Clinical;Clinical Research;clinical trial enrollment;clinical trial participant;Clinical Trials;clinically relevant;Country;Data Analyses;Data Coordinating Center;data management;data registry;Data Sources;design;Diagnosis;effectiveness evaluation;EFRAC;Elements;Enrollment;Ensure;Event;evidence base;experience;follow-up;Funding;Guidelines;Heart Arrest;Heart failure;heart failure with reduced ejection fraction;Hospitalization;Incidence;Individual;Information Dissemination;Intervention Trial;Lead;Left Ventricular Ejection Fraction;Medical;Meta-Analysis;Methodology;Mineralocorticoid Receptor;Morbidity - disease rate;mortality;North America;Outcome;Participant;participant enrollment;Patients;Pharmaceutical Preparations;Placebos;Population;Pragmatic clinical trial;pragmatic trial;preservation;Prevalence;primary endpoint;primary outcome;Public Health;Randomized;randomized, clinical trials;Registries;Research;Research Institute;Research Personnel;Russia;secondary analysis;secondary endpoint;secondary outcome;South America;Specific qualifier value;Spironolactone;standard of care;Sweden;symptomatic improvement;Telephone;Testing;Therapeutic;Therapeutic Intervention;Time;treatment as usual;trial enrollment;United States

PROJECT_TITLE: 2/2 Data Coordinating Center for the Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction Study (SPIRRIT-EX)


ORG_CITY: NASHVILLE

ORG_NAME: VANDERBILT UNIVERSITY MEDICAL CENTER

ORG_STATE: TN

PHR: PROJECT NARRATIVE The BP4 consortium brings together experts in virology, immunology, vaccine sciences, and antibody discovery to perform advanced research on prototype pathogens for Picornaviruses and Bunyaviruses. The group will develop both protective antiviral human antibodies (passive immunity) and vaccines (active immunity) for each of the viral pathogens studied. The highly interactive consortium will leverage lessons learned in the antibody studies of sites of vulnerability on the viruses to develop and test new vaccine concepts that can be extended from one prototype pathogen to all members of that class of viruses.

PI_NAMEs: CROWE, JAMES E (contact)

PROJECT_TERMS: Academia;Acceleration;Active immunity;Adenoviruses;Age;Animal Model;Animals;Antibodies;Antibody Therapy;Antigens;Arenavirus;Authorization documentation;Awareness;Basic Science;BIK gene;Biological Warfare;Biology;Chimera organism;circular RNA;Clinic;cohort;COVID-19;data management;Data Management Resources;data sharing;design;Development;Devices;Disease;Disease Outbreaks;Distant;DNA;Echo Viruses;Electroporation;Enrollment;Enterovirus 68;Enterovirus 71;experience;Experimental Animal Model;Family;Family Picornaviridae;first responder;Goals;Half-Life;Hantavirus;Health;Hendra;high risk;Human;human monoclonal antibodies;Human Resources;Immunity;Immunocompromised Host;Immunoglobulin G;Immunologics;Immunology;Individual;Industry;industry partner;Infection;Injections;innovation;insight;Laboratories;Lead;Learning;Lymphocytic choriomeningitis virus;medical countermeasure;member;Military Personnel;Modeling;Monoclonal Antibodies;Mutation;neglect;Nipah;novel;novel vaccines;Nucleic Acid Vaccines;Orthobunyavirus;pandemic pathogen;Passive Immunity;pathogen;Pathogenesis;pathogenic virus;Pathogenicity;Population;Preparation;Prevention;Preventive vaccine;product development;programs;Prophylactic treatment;prototype;Public Health;Readiness;Reagent;Reporter Genes;Research;Research Personnel;Research Project Grants;Resources;response;Rhinovirus;RNA;Sampling;Science;Site;structural biology;success;Technology;Testing;Therapeutic;therapeutic candidate;Time;vaccine candidate;vaccine development;vaccine strategy;vaccine-induced antibodies;Vaccines;vector vaccine;Vesicular stomatitis Indiana virus;Viral;virology;Virus;Virus Diseases;Virus-like particle;Work

PROJECT_TITLE: Bunyavirus and Picornavirus Pandemic Pathogen Preparedness (BP4) Center


PROJECT_TERMS: Agreement;BIK gene;Communication;Communities;data communication;data sharing;Family Picornaviridae;industry partner;Leadership;meetings;Monitor;National Institute of Allergy and Infectious Disease;Occupational activity of managing finances;operation;Organization administrative structures;Orthobunyavirus;pandemic pathogen;Play;programs;Progress Reports;Readiness;Research Project Grants;Role;Services;Travel;Vaccines

PROJECT_TITLE: Admin-Core


PI_NAMEs: SLAUGHTER, JAMES CHRISTOPHER (contact)

PROJECT_TERMS: archive data;BIK gene;Biometry;Biostatistical Methods;Collaborations;collaborative environment;Collection;Communicable Diseases;Data;data integrity;data management;data quality;data repository;Data Security;data sharing;data submission;Databases;Deposition;Disease;Doctor of Philosophy;Electron Microscopy;Ensure;Epitopes;expectation;Family Picornaviridae;Fostering;Future;Genbank;Immune;Immunology;Infrastructure;interoperability;Link;Literature;Manuscripts;meetings;Metadata;Orthobunyavirus;pandemic pathogen;preservation;protein data bank;public database;public repository;Publishing;Quality Control;Readiness;repository;Research Personnel;Research Project Grants;Secure;Sequence Read Archive;sound;Vaccines;Virus;Work

PROJECT_TITLE: Data-Management-Core


PI_NAMEs: KUHN, RICHARD J. (contact)

PROJECT_TERMS: Academic Medical Centers;Antibodies;Antibody Affinity;Antibody Binding Sites;Antibody Therapy;Antigen Presentation;Antigen Targeting;Antigen-Antibody Complex;Antigens;Arenavirus;Assessment tool;Awareness;Binding;Biology;biophysical analysis;biophysical techniques;Biophysics;Bunyavirales;Calorimetry;Capsid Proteins;Collaborations;Complex;Computational Biology;Containment;Cryoelectron Microscopy;Data;data exchange;data management;data repository;data sharing;data submission;Databases;design;Development;Disease Outbreaks;Disparate;Electron Microscopy;Engineering;Ensure;Enterovirus;Epitopes;experience;Family Picornaviridae;Genome;Glycoproteins;Goals;Hantavirus;human disease;Immune;Immune response;insight;Interferometry;Junin virus;Kinetics;Laboratories;Lassa;Ligands;Lymphocytic choriomeningitis virus;Molecular;Monoclonal Antibodies;Nature;Orthobunyavirus;pandemic pathogen;pandemic potential;pandemic virus;particle;pathogen;pathogens of pandemic potential;prediction algorithm;Production;Protein Analysis;protein data bank;protein protein interaction;Proteins;prototype;Readiness;Reagent;Research;Resources;Rhinovirus;RNA Viruses;Site;Specificity;structural biology;Structure;Surface Plasmon Resonance;Techniques;Technology;Thermodynamics;Time;Titrations;tool;transmission process;United States National Institutes of Health;Universities;vaccine development;vaccine platform;Vaccines;Viral Proteins;Virion;Virus;Virus-like particle;Work;X-Ray Crystallography

PROJECT_TITLE: Structural Biology Core


PI_NAMEs: CARNAHAN, ROBERT H (contact)

PROJECT_TERMS: Adenovirus Vector;animal efficacy;Antibodies;BIK gene;candidate selection;circular RNA;Communicable Diseases;Complex;delivery vehicle;Dependence;design;Development;DNA delivery;efficacy study;Electroporation;Engineering;Ensure;Evaluation;Family Picornaviridae;flexibility;Generations;Goals;Grant;Health;Joints;Lead;lead candidate;lipid nanoparticle;manufacturing process;medical countermeasure;Modality;Modification;Monoclonal Antibodies;new technology;novel vaccines;nucleic acid delivery;Nucleic Acids;Orthobunyavirus;pandemic pathogen;Process;Production;Provider;Quality Control;Readiness;Reagent;Recombinant Antibody;Recombinant Proteins;recombinant virus;Recombinants;Research;Research Personnel;Research Project Grants;Rhesus;RNA;Services;Support System;System;Technology;technology platform;Test Result;Testing;Therapeutic;Therapeutic antibodies;Therapeutic Monoclonal Antibodies;Vaccine Antigen;vaccine candidate;vaccine delivery;vaccine platform;vaccine-induced antibodies;Vaccines;Viral Vaccines;Viral Vector;Virus-like particle;Work;working group

PROJECT_TITLE: Vaccines and Therapeutics Technology Core


PI_NAMEs: KIMBERLIN, DAVID W (contact)

PROJECT_TERMS: Adult;Antibodies;Antigens;B cell repertoire;Basic Science;BIK gene;biobank;Biological;Blood;Blood specimen;Child;Circulation;cohort;Collection;Development;emerging pathogen;emerging virus;Enrollment;Ensure;Evaluation;experience;Exposure to;Family;Family Picornaviridae;Funding;future pandemic;Geographic Locations;Geography;Human;Immune;Immune response;Immunity;Immunologic Epidemiology;Immunologic Surveillance;Immunologics;improved;Infection;interest;International;Liquid substance;Longitudinal cohort;microbial;Mucosal Immune Responses;Mucous Membrane;neutralizing antibody;Orthobunyavirus;pandemic pathogen;pandemic potential;pandemic response;pathogen;Peripheral Blood Mononuclear Cell;Persons;Pilot Projects;Plasma;Population Heterogeneity;Primary Infection;Process;prototype;Readiness;repository;Research Project Grants;sample collection;Sampling;screening;Seasons;seroconversion;Serum;Site;Specimen;Surveys;Symptoms;T-Lymphocyte;Therapeutic;Therapeutic Monoclonal Antibodies;Translational Research;United States National Institutes of Health;Vaccination;vaccine candidate;vaccine development;Vaccines;Viral;viral detection;Virus;Virus Shedding;Work

PROJECT_TITLE: Virologic and Immunologic Sample Acquisition Core


PI_NAMEs: ANDINO, RAUL  (contact)

PROJECT_TERMS: Acceleration;Acute;adaptive immune response;adaptive immunity;Adjuvant;Age;Animal Model;Antigens;asthma exacerbation;B-Lymphocytes;BIK gene;Biological Assay;Brain Stem;Bronchiolitis;Bronchitis;Cellular Immunity;Child;Complex;Coxsackie Viruses;Dangerousness;design;Development;Disease;Disease Outbreaks;DNA cassette;Echo Viruses;Encephalitis;Ensure;Enterovirus;Enterovirus 68;Enterovirus 71;Environment;Epitopes;Family Picornaviridae;fighting;Foundations;gastrointestinal system;Gastrointestinal tract structure;Health;Human;human monoclonal antibodies;human pathogen;Immune response;Immunocompetent;immunogenic;immunogenicity;Immunologic Memory;Immunology;in vivo;Industry;Infection;innovation;Knowledge;Lead;Life;Medical;Modeling;Molecular Biology;Monoclonal Antibodies;mouse model;Mucosal Immune Responses;Mucosal Immunity;mucosal vaccination;Mucous Membrane;neonatal sepsis;Nervous System Disorder;novel;novel vaccines;Nucleic Acids;Orthobunyavirus;Otitis;pandemic pathogen;Paralysed;pathogen;Pathogenicity;Peptide Hydrolases;Persons;Pneumonia;Population;pre-clinical;prevent;Process;Property;Proteins;prototype;Readiness;Reagent;Research;Research Personnel;Research Project Grants;Respiratory System;response;Rhinovirus;Risk Reduction;RNA;RNA replication;Site;Structure;Surface;Surrogate Markers;System;T-Lymphocyte;Technology;Testing;tool;United States;Upper Respiratory Infections;Vaccination;vaccination strategy;vaccine candidate;Vaccine Design;vaccine development;vaccine formulation;vaccine immunogenicity;vaccine platform;vaccine safety;vaccine-induced immunity;Vaccines;viral transmission;Virion;Virus;Virus Diseases;Virus-like particle;Wheezing

PROJECT_TITLE: Design and testing picornavirus vaccine candidates


PI_NAMEs: VOGT, MATTHEW R (contact)

PROJECT_TERMS: academic preparation;acute flaccid myelitis;Animals;Antibodies;Antibody Response;Antibody-mediated protection;Antigenic Diversity;Asthma;B-Lymphocyte Epitopes;B-Lymphocytes;BIK gene;Binding;biobank;Biological Assay;Capsid Proteins;Cell Culture Techniques;Cell Line;Child;Chronic lung disease;citrate carrier;Clinical;clinical development;cohort;Collaborations;Common Cold;Coxsackie Viruses;Cryoelectron Microscopy;Data;Development;Disease;Echo Viruses;emerging pathogen;Enteral;Enterovirus;Enterovirus 68;Enterovirus 71;Enzyme-Linked Immunosorbent Assay;Epidemic;Epitopes;experience;Family Picornaviridae;Foot Diseases;Funding;Future;future pandemic;gastrointestinal;Goals;Hand's disease;Health;Human;human monoclonal antibodies;Humoral Immunities;Hybridomas;Immune response;Immunity;Immunologics;In Vitro;in vivo;Individual;Industry;industry partner;Infection;Laboratories;Learning;Licensing;Life;Mammalian Cell;manufacture;Maps;Mediating;member;Meningitis;Methods;Modeling;Monoclonal Antibodies;Mouth Diseases;Mucous Membrane;Mus;Myocarditis;National Institute of Allergy and Infectious Disease;neonatal sepsis;neonate;neutralizing antibody;neutralizing monoclonal antibodies;novel;nucleic acid delivery;Orthobunyavirus;pandemic disease;pandemic pathogen;Paralysed;pathogen;Pathogenicity;Pattern;Peptides;phase I trial;Phylogenetic Analysis;Picornaviridae Infections;Poliomyelitis;Poliovirus Vaccines;polyclonal antibody;pre-clinical;Pre-Clinical Model;preservation;Production;programs;Property;Prophylactic treatment;protective efficacy;Protocols documentation;prototype;Quality Control;Readiness;Reagent;Recording of previous events;Reporter;Research Proposals;respiratory;Respiratory Mucosa;response;Rhinovirus;Sampling;Schedule;screening;Sepsis;seroconversion;Serum;Services;Site;Specimen;Speed;structural biology;Surface;System;Techniques;Technology;Testing;Therapeutic Uses;Time;tool;vaccine candidate;vaccine development;vaccine platform;Vaccinee;Vaccines;Viral;Virion;Virus;Virus Replication;Wheezing;Work

PROJECT_TITLE: Protective human antibodies for picornaviruses


PI_NAMEs: BUKREYEV, ALEXANDER  (contact)

PROJECT_TERMS: Andes Virus;Animal Model;Animals;Antibody Response;Arenavirus;BIK gene;Bunyavirales;circular RNA;Clinical Trials;cold temperature;comparative;Data;Development;Disease Outbreaks;DNA;DNA Vaccines;efficacy testing;Encapsulated;experience;Family;Family Picornaviridae;Formulation;Funding;Hantaan virus;Hantavirus;Human;human disease;Immune response;immunogenicity;Industrialization;industry partner;Infection;innovation;insight;Investigation;Knowledge;knowledge of results;Lead;Licensing;lipid nanoparticle;medical countermeasure;Messenger RNA;mRNA lipid nano particle vaccine;nanoparticle;nanopolymer;Nucleic Acid Vaccines;Orthobunyavirus;pandemic pathogen;pandemic potential;Preclinical Testing;protective efficacy;Proteins;Readiness;Research Project Grants;Research Project Summaries;response;RNA;RNA vaccine;Sin Nombre virus;stability testing;Temperature;transmission process;vaccination strategy;vaccine immunogenicity;vaccine platform;Vaccines;Virus;Virus Diseases;Work

PROJECT_TITLE: Nucleic acid vaccines targeting hantaviruses


PROJECT_TERMS: Active Immunization;Address;Affinity;Agreement;Americas;Andes Virus;Animal Model;Antibodies;Antibody Repertoire;Antibody-mediated protection;Antigens;Avidity;B-Lymphocytes;Back;BIK gene;Binding;biobank;Cardiopulmonary;Cell Line;Cell Separation;Characteristics;Chinese Hamster Ovary Cell;clinically relevant;Collection;Combined Modality Therapy;Complex;Cyclic GMP;Data;design;Development;Disease;Dose;Engineering;Epidemic;Epitopes;Evaluation;Family;Family Picornaviridae;Future;future epidemic;Gene Modified;Goals;Half-Life;Hantaan virus;Hantavirus;Hantavirus Infections;Hemorrhagic Fever with Renal Syndrome;high throughput screening;Human;human disease;human monoclonal antibodies;Hybridomas;Immune;Immunity;In Vitro;in vivo;Individual;industry partner;Infection;Injections;insight;Investigation;Knowledge;Lead;Learning;manufacture;Mediating;medical countermeasure;Membrane Proteins;Memory B-Lymphocyte;Methods;Modeling;Molecular;Monoclonal Antibodies;Morbidity - disease rate;mortality;National Institute of Allergy and Infectious Disease;neutralizing antibody;neutralizing monoclonal antibodies;novel;Orthobunyavirus;Pan Genus;pandemic pathogen;Passive Immunization;pathogen;Performance;Preparation;prevent;Production;programs;Property;Proteins;prototype;Readiness;Reagent;receptor;Recombinants;Research Personnel;Rodent;Role;Sampling;Sin Nombre virus;single cell sequencing;single-cell RNA sequencing;Site;Surface;Syndrome;synergism;Techniques;Technology;Testing;Therapeutic;therapeutic candidate;therapeutic evaluation;Therapeutic Intervention;therapeutic vaccine;therapeutically effective;Treatment Efficacy;Vaccine Antigen;vaccine development;Vaccines;virtual;Virus;Virus Diseases;Virus Replication;Work;Zoonoses

PROJECT_TITLE: Human monoclonal antibodies for hantaviruses


PROJECT_TERMS: Active immunity;Adenovirus Vector;Antibodies;Area;Arenavirus;Attenuated;BIK gene;Blood Vessels;Clinical;clinical development;Collaborations;Combined Modality Therapy;Data;data management;design;Development;Disease;DNA delivery;Epitopes;experience;Extravasation;Family;Family Picornaviridae;Genes;Half-Life;Hantavirus;Human;human monoclonal antibodies;Immune;Immune response;Immunity;Immunocompromised Host;immunogenicity;industry partner;Infection;Injections;insight;Junin virus;Lassa virus;Lead;lead candidate;Lymphocytic choriomeningitis virus;Macaca;Macaca mulatta;manufacturing capabilities;Medical;medical countermeasure;Meningitis;Messenger RNA;Modeling;Monoclonal Antibodies;Mutation;neutralizing monoclonal antibodies;nonhuman primate;Orthobunyavirus;pandemic pathogen;pandemic potential;pandemic preparedness;Passive Immunity;pathogen;Pathogenesis;pathogenic virus;Pathogenicity;pre-clinical;preclinical development;prophylactic;protective efficacy;Proteins;prototype;Readiness;Reagent;Resistance;Response Generalization;Role;Syndrome;synergism;T cell response;T-Lymphocyte;Technology;technology platform;Therapeutic;Therapeutic antibodies;therapeutic development;vaccine candidate;Vaccine Design;vaccine evaluation;vaccine platform;vaccine strategy;vaccine-induced immunity;Vaccines;vector;vector vaccine;Viral Hemorrhagic Fevers;Virus;Virus Diseases;Work

PROJECT_TITLE: Vaccines and antibodies for arenaviruses


NIH_SPENDING_CATS: Antimicrobial Resistance;Biodefense and Related Countermeasures;Bioengineering;Clinical Research;Data Science;Emerging Infectious Diseases;Infectious Diseases;Machine Learning and Artificial Intelligence;Networking and Information Technology R&D (NITRD);Sexually Transmitted Infections

ORG_NAME: MASSACHUSETTS GENERAL HOSPITAL

PHR: PROJECT NARRATIVE  The discovery of new antibiotics for Neisseria gonorrhoeae is relevant to public health due to the increasing prevalence of strains that have developed resistance to ceftriaxone, which is the last remaining highly effective antibiotic treatment and the standard first-line treatment globally. This project will apply a new approach to antibiotic discovery in N. gonorrhoeae by using machine learning to virtually screen hundreds of millions of chemicals for antibacterial activity. This approach promises to address the pressing need for new antibiotics and stave off the threat of untreatable gonorrhea.

PI_NAMEs: ANAHTAR, MELIS N. (contact)

PROGRAM_OFFICER_NAME: CONNOLLY, KRISTIE LEE

PROJECT_TERMS: Address;Adult;Advisory Committees;Animal Model;Anti-Bacterial Agents;Antibiotic Resistance;Antibiotic Therapy;Antibiotics;antimicrobial;Antimicrobial Resistance;Award;Azithromycin;Bacterial Drug Resistance;Biological;Blindness;Bypass;career development;Ceftriaxone;Cells;cellular targeting;Cessation of life;Chemical Structure;Chemicals;Clinical;Clinical Pathology;Clinical Trials;computerized tools;Data;design;Development;Development Plans;Diagnosis;Diagnostic;Doctor of Philosophy;drug development;drug discovery;Drug Kinetics;Drug resistance;drug resistant bacteria;drug-like compound;Drug-resistant Neisseria Gonorrhoeae;Environment;experience;experimental study;Foundations;Frequencies;Future;General Hospitals;Genetic;Genomic approach;Genomics;Goals;Gonorrhea;Gram-Negative Bacteria;graph neural network;Growth;Health;HIV;Human;improved;in silico;In Vitro;in vivo;in vivo evaluation;indexing;Infant;Infection;Infertility;innovation;insight;Investigation;K-Series Research Career Programs;Knowledge;Learning;Left;Libraries;Life;Machine Learning;machine learning model;machine learning prediction;Massachusetts;Mentors;Mentorship;Microscopic;Modeling;Molecular;Molecular Target;mouse model;Multi-Drug Resistance;Neisseria gonorrhoeae;Neonatal;Neural Network Simulation;novel;novel strategies;Organism;Persons;Pharmaceutical Chemistry;Pharmaceutical Preparations;Pharmacotherapy;Phenotype;Physicians;Postdoctoral Fellow;pre-clinical;Predisposition;Pregnancy Complications;Prevalence;Property;Proteomics;Public Health;Reporting;Research;research and development;Research Personnel;Resistance;Resistance development;resistance mechanism;Resources;Risk;Scientist;screening;Series;Sexual Transmission;skills;small molecule libraries;Structure;Testing;Therapeutic Intervention;Tissues;Toxic effect;Training;training data;Treatment Failure;vaginal infection;vaginal microbiome;virtual;virtual screening;Work

PROJECT_TITLE: Harnessing machine learning to develop new antibiotics for Neisseria gonorrhoeae

STUDY_SECTION: MID

STUDY_SECTION_NAME: Microbiology and Infectious Diseases B Research Study Section[MID-B]


ED_INST_TYPE: SCHOOLS OF PUBLIC HEALTH

NIH_SPENDING_CATS: Biodefense and Related Countermeasures;Comparative Effectiveness Research;Data Science;Emerging Infectious Diseases;Infectious Diseases;Machine Learning and Artificial Intelligence;Prevention;Vector-Borne Diseases

ORG_CITY: CHAPEL HILL

ORG_NAME: UNIV OF NORTH CAROLINA CHAPEL HILL

PHR: PROJECT NARRATIVE Estimating effects of infectious disease interventions is challenging when study samples do not reflect the target populations where intervention policies will be applied or when the outcomes of individuals are dependent on the treatments of other individuals. The proposed study will bring together the fields of generalizability and interference to estimate intervention effects using data from cluster randomized trials and observational studies. This work will allow for more accurate estimation of intervention effects in a variety of practical settings.

PI_NAMEs: SHOOK-SA, BONNIE E (contact)

PROGRAM_OFFICER_NAME: GEZMU, MISRAK

PROJECT_TERMS: 2019-nCoV;Address;Age;antiretroviral therapy;Area;Beds;Behavior;Behavior Therapy;career;Censuses;Cessation of life;Characteristics;Child;Cluster randomized trial;Code;Communicable Diseases;Communication;Communities;Complex;Data;Data Science;Demographic Factors;density;design;Development;Disease;disorder prevention;Eligibility Determination;Ensure;Epidemiology;flexibility;Foundations;Goals;HIV;Human immunodeficiency virus test;hutterite;improved;Incidence;Individual;Infection;Infectious Disease Epidemiology;Infectious Diseases Research;Influenza prevention;influenza virus vaccine;innovation;interest;Intervention;intervention effect;low income country;Machine Learning;machine learning algorithm;machine learning method;Malaria;Masks;Medical;Mentored Research Scientist Development Award;Mentors;Methods;Observational Study;Outcome;Participant;Persons;Policies;Population;population based;population health;Population Intervention;Prevalence;prevent;preventive intervention;Probability;Property;Randomized;randomized trial;Research;Research Design;Risk;Risk Factors;Sampling;Sampling Studies;Scientist;simulation;South Africa;Statistical Methods;statistics;study characteristics;Surveys;Target Populations;Testing;Training;transmission process;treatment as prevention;Uganda;Use Effectiveness;user-friendly;Weight;Work;Zambia

PROJECT_TITLE: Generalizing Effects of Infectious Disease Prevention Interventions in the Presence of Interference


ADMINISTERING_IC: AA

IC_NAME: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

NIH_SPENDING_CATS: Alcoholism, Alcohol Use and Health;Behavioral and Social Science;Bioengineering;Brain Disorders;Clinical Research;Clinical Trials and Supportive Activities;Neurosciences;Substance Misuse

ORG_CITY: STANFORD

ORG_DEPT: PSYCHIATRY

ORG_NAME: STANFORD UNIVERSITY

PHR: Narrative Alcohol Use Disorders are currently positioned as the third leading cause of preventable death in the United States, several within 6 stimulation (TMS), a constituting a humanitarian crisis with substantial financial burden on society and medical facilities. While pharmacological interventions exist, 60% of individuals who seek these treatments relapse to alcohol months. The current proposal seeks to improve upon the clinical efficacy of transcranial magnetic form of non-invasive brain stimulation, by developing personalized, fMRI-guided TMS as a strategy to reduce brain reactivity to alcohol cues and reduce relapse rates.

PI_NAMEs: MCCALLEY, DANIEL  (contact)

PROGRAM_OFFICER_NAME: GRAKALIC, IVANA

PROJECT_TERMS: Acceleration;Adherence;Age;Alcohol consumption;alcohol cue;alcohol response;alcohol use disorder;Alcohols;Anterior;Area;Award;Behavioral;Biological Markers;Brain;Brain region;career;Cephalic;Cessation of life;Clinical;clinical efficacy;Clinical Trials;Clinical Trials Design;complex modeling;Corpus striatum structure;cue reactivity;Cues;Data;Data Set;Development;Dorsal;Dose;Double-Blind Method;drinking;drug seeking behavior;effective intervention;efficacy evaluation;electric field;Electromagnetics;Environment;experience;Experimental Designs;experimental study;Financial Hardship;follow-up;Functional Magnetic Resonance Imaging;Future;Goals;Habits;Human;improved;Individual;innovation;interest;Intervention;Laboratories;Leadership;Linear Models;Location;Magnetism;Medial;Medical;Methods;Modeling;National Institute on Alcohol Abuse and Alcoholism;neural;neural circuit;neuroimaging;noninvasive brain stimulation;novel;novel strategies;Obsession;Obsessive compulsive behavior;Outcome;Patient Self-Report;Patients;Pattern;pharmacologic;Pharmacological Treatment;Phase;Physiologic pulse;Positioning Attribute;Prefrontal Cortex;preventable death;prospective;Questionnaires;Randomized;recruit;Relapse;relapse prediction;Research Personnel;response;Rodent;Scalp structure;Scanning;Series;sex;sham-controlled study;sobriety;Societies;Source;Spatial Distribution;statistics;Symptoms;Temporal Lobe;Therapeutic;tool;Training;Transcranial magnetic stimulation;Treatment Efficacy;Treatment outcome;United States;Visual

PROJECT_TITLE: Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder

STUDY_SECTION: AA

STUDY_SECTION_NAME: Neuroscience and Behavior Study Section[AA-4]


NIH_SPENDING_CATS: Antimicrobial Resistance;Biodefense and Related Countermeasures;Bioengineering;Biotechnology;Clinical Research;Clinical Trials and Supportive Activities;Emerging Infectious Diseases;Genetics;Health Services;Human Genome;Infectious Diseases;Lung;Nanotechnology;Orphan Drug;Patient Safety;Precision Medicine;Prevention;Rare Diseases;Social Determinants of Health;Tuberculosis

PHR: Project Narrative Globally, tuberculosis is one of the leading causes of death by an infectious disease, and there is a critical need to develop new tools to enable early diagnosis and improve treatment and prevention. The proposed K24 award would support Dr. Andrews to mentor early career investigators in patient-oriented translational research. The focus of the proposed research is to test novel approaches to early diagnosis and pharmacogenomic approaches to optimize treatment and preventive therapy.

PI_NAMEs: ANDREWS, JASON RANDOLPH (contact)

PROGRAM_OFFICER_NAME: MENDEZ, SUSANA

PROJECT_TERMS: Acceleration;Adverse event;adverse event risk;Americas;antigen detection;Antigens;Award;Back;Benchmarking;Biological Assay;Brazil;care seeking;career;case finding;Cause of Death;Cessation of life;Clinical Research;Clinical Trials;cohort;Collaborations;Communicable Diseases;cost;COVID-19 pandemic;CYP3A5 gene;Detection;detection assay;Development;Diagnosis;DNA;Dose;Drug Kinetics;drug metabolism;Drug toxicity;Drug usage;Early Diagnosis;effective therapy;Enzymes;Exhalation;Focus Groups;Funding;Gene Expression;Genetic Polymorphism;Genetic Transcription;Genomics;Goals;Haplotypes;Health care facility;high risk population;Home;Human;Immunoassay;Imprisonment;improved;Incidence;Individual;innovation;isoniazid;K-Series Research Career Programs;Laboratories;Linezolid;Lipids;lipoarabinomannan;Measures;Mentors;Mentorship;Metabolism;Mid-Career Clinical Scientist Award (K24);Morbidity - disease rate;mortality;Multidrug-Resistant Tuberculosis;Mycobacterium tuberculosis;Mycobacterium tuberculosis antigens;nanopore;next generation;novel;novel strategies;Oral;Participant;patient oriented;patient oriented research;Patient Selection;Patients;personalized medicine;Pharmaceutical Preparations;Pharmacogenomics;Physical condensation;Physicians;Pilot Projects;Postdoctoral Fellow;prevent;Prevention;Prevention Measures;Preventive therapy;Preventive treatment;Prisons;Proteins;Regimen;Research;Research Personnel;Resource-limited setting;Rifampicin resistance;rifapentine;Risk;risk prediction;Roentgen Rays;Sampling;Scientist;screening;skills;Specificity;Sputum;Students;targeted treatment;Testing;Time;tool;Toxic effect;Training;Translational Research;translational study;transmission process;treatment optimization;Tuberculosis;Tuberculosis diagnosis;tuberculosis drugs;tuberculosis treatment;United States National Institutes of Health;Variant;virtual

PROJECT_TITLE: Mentoring patient-oriented translational research in tuberculosis

STUDY_SECTION_NAME: Microbiology and Infectious Diseases Research Study Section[MID]


ORG_CITY: SAINT LOUIS

ORG_NAME: WASHINGTON UNIVERSITY

ORG_STATE: MO

PHR: NARRATIVE The R2P2 ReVAMPP Center aims to develop vaccines and antibody-based treatments for viruses in the Paramyxoviridae, Peribunyaviridae, and Phleboviridae families. The center focuses on four primary research projects, working alongside key scientific cores to investigate prototype viruses and use principles of reverse vaccinology to understand immunity and antigenicity. The projects compare three vaccine platforms (protein subunit, mRNA, and chimeric VSV) to gather information about their performance in translating to related pathogens.

PI_NAMEs: MOSCONA, ANNE ;RAPPUOLI, RINO ;WHELAN, SEAN PJ (contact)

PROJECT_TERMS: Amino Acid Sequence;Animal Disease Models;Animal Model;Antibodies;Antibody Therapy;Antigens;Binding;Biological Assay;Biology;biophysical analysis;Biophysics;Bunyavirales;Cells;Cellular Immunity;Characteristics;Chiroptera;Collaborations;data management;design;Development;Disease;efficacy testing;emerging virus;Ensure;env Gene Products;Evaluation;experience;experimental study;Family;Genetic;Glycoproteins;Goals;Hand;Human;human monoclonal antibodies;Immune;Immunity;Immunologist;Immunology;in vivo;Industry;industry partner;Infection;information gathering;insight;Knowledge;La Crosse virus;Leadership;Measures;Membrane Fusion;Messenger RNA;Molecular;Monoclonal Antibodies;Mumps;Mumps virus;Mus;Nature;next generation;novel strategies;Oropouche virus;pandemic preparedness;Para-Influenza Virus Type 1;Para-Influenza Virus Type 3;parainfluenza virus;Paramyxovirus;pathogen;Pathway interactions;Performance;Peripheral Blood Mononuclear Cell;Process;Productivity;prophylactic;Protein Engineering;protein function;protein structure;Protein Subunits;Proteins;prototype;receptor;receptor binding;Recombinant Proteins;Recombinants;Recording of previous events;Research Personnel;Research Project Grants;Resistance;Respirovirus;response;Rift Valley Fever;Rift Valley fever virus;RNA;Rubulavirus;Site;structural biology;Structure;technology platform;Testing;Therapeutic;Therapeutic antibodies;Therapeutic Monoclonal Antibodies;therapeutic vaccine;Toscana virus;Translating;vaccine candidate;vaccine development;vaccine platform;vaccine-induced antibodies;Vaccines;vaccinology;vector;vector vaccine;Vesicular stomatitis Indiana virus;Viral;Viral Envelope Proteins;Viral Physiology;Virus;Virus Diseases;Work

PROJECT_TITLE: Vaccines and Therapeutic Antibodies to Respiro, Rubula, Peribunya and Phenuiviridae (R2P2)-ReVAMPP


PI_NAMEs: WHELAN, SEAN PJ (contact)

PROJECT_TERMS: Accountability;Address;Caring;Collaborations;collaborative environment;Communication;Complement;Core Facility;cost;Data;data integration;data management;data sharing;Decision Making;Development;Ensure;Evaluation;experience;experimental study;Financial Support;Fostering;Funding;Goals;Government Agencies;Industrialization;Institution;Intellectual Property;Investigator-Initiated Research;Joints;Laboratories;Laboratory Animals;Leadership;Manuscripts;Mediation;meetings;member;Mentors;Mission;Monitor;National Institute of Allergy and Infectious Disease;Occupational activity of managing finances;Play;Preparation;Principal Investigator;Process;product development;programs;Progress Reports;Publications;Reagent;Recommendation;Reporting;Research;research and development;Research Contracts;Research Personnel;Research Project Grants;Research Support;Resource Sharing;Resources;Respirovirus;Role;Rubulavirus;Safety;Scientific Evaluation;Series;Site Visit;Structure;success;System;Therapeutic antibodies;Travel;vaccine-induced antibodies;Visit;web site;Work

PROJECT_TITLE: Core A:  Administrative Core


PI_NAMEs: MILLER, J. PHILIP (contact)

PROJECT_TERMS: Acceleration;Agreement;Antigens;Applied Skills;Archives;Artificial Intelligence;Chi-Square Tests;classification trees;cloud based;Collection;Communities;dashboard;Data;data access;Data Analyses;Data Discovery;data handling;data harmonization;data management;Data Management Resources;data mining;data modeling;Data Provenance;data reuse;Data Set;data sharing;data sharing networks;Data Storage and Retrieval;Databases;design;Documentation;Ensure;FAIR principles;Foundations;Future;Graph;improved;indexing;Information Dissemination;Information Systems;innovation;interoperability;Language;Libraries;Linear Models;Machine Learning;Manuscripts;member;Metadata;Methods;Modernization;Ontology;Play;Policies;Protocols documentation;prototype;random forest;Reporting;Reproducibility;Research;Research Personnel;Respirovirus;Rubulavirus;Running;Science;Site;skills;Specific qualifier value;Standardization;Support System;synergism;System;Techniques;Technology;Testing;Therapeutic antibodies;Time;timeline;Universities;Update;user-friendly;vaccine platform;vaccine-induced antibodies;Visualization;Washington;Work

PROJECT_TITLE: Core B:  Data Management Core


PI_NAMEs: MCLELLAN, JASON SCOTT (contact)

PROJECT_TERMS: 2019-nCoV;Address;Antibodies;Antigen-Antibody Complex;Antigens;B-Lymphocytes;Binding;Binding Proteins;biophysical properties;biophysical techniques;Cell membrane;Cell Separation;Chimeric Proteins;Chromatography;Complex;Computing Methodologies;Consultations;Cryoelectron Microscopy;design;Deuterium;Development;Diagnostic Reagent;Engineering;Ensure;Epitopes;experience;experimental study;flexibility;Glycoproteins;Hydrogen;Image;Immune response;Immune system;immunogenicity;insight;Interferometry;Intervention;Investigation;Knowledge;Laboratories;light scattering;Machine Learning;Mammalian Cell;Maps;Mass Spectrum Analysis;Mediating;medical countermeasure;Membrane;Membrane Glycoproteins;Membrane Proteins;Methods;Mission;Modeling;Modification;Molecular;Molecular Conformation;Molecular Machines;Monoclonal Antibodies;mRNA delivery;Orthobunyavirus;pandemic preparedness;Paramyxovirus;particle;pathogen;pathogenic virus;Play;Process;Production;protein complex;Protein Engineering;protein purification;protein structure;Proteins;prototype;rational design;receptor;Receptor Cell;Research Project Grants;Resolution;Respiratory Syncytial Virus Vaccines;Respirovirus;Role;Rubulavirus;Scanning;Services;structural biology;Structure;Subunit Vaccines;Surface;Techniques;Texas;Therapeutic antibodies;Universities;Vaccine Antigen;vaccine development;vaccine-induced antibodies;Vaccines;Variant;Viral;Viral Physiology;Viral Proteins;Virion;virology;Virus;Visual;Work;X-Ray Crystallography

PROJECT_TITLE: Core C:  Structure Core


PI_NAMEs: ELLEBEDY, ALI HASSAN (contact)

PROJECT_TERMS: Address;Affinity;Age Months;Antibodies;Antibody Response;Antibody titer measurement;Antigens;B-Lymphocytes;Binding;Biophysics;Blood;candidate identification;Cell Separation;Centers for Disease Control and Prevention (U.S.);Child;Chiroptera;cohort;Collaborations;Collecting Cell;Consent;Coronavirus spike protein;COVID-19 vaccine;Democratic Republic of the Congo;design;Development;Dose;Enrollment;epidemic potential;epidemic virus;Epitopes;Family;Funding;Future;Generations;Glycoproteins;Goals;Health;High Prevalence;Human;human monoclonal antibodies;Immune;Immunization;immunogenicity;Immunoglobulins;Immunologics;In Vitro;in vivo;Individual;Infection;insight;Institutional Review Boards;Italy;Kenya;Knowledge;La Crosse virus;Laboratories;Lacrosse;Letters;Maps;Measles-Mumps-Rubella Vaccine;Measures;Membrane Proteins;Memory B-Lymphocyte;Messenger RNA;Monoclonal Antibodies;Mumps;Mumps virus;Mus;neutralizing antibody;neutralizing monoclonal antibodies;novel;Oropouche virus;pandemic potential;pandemic virus;Para-Influenza Virus Type 1;Para-Influenza Virus Type 3;Parainfluenza Virus Infections;Paramyxovirus;pathogen;Patients;Peripheral Blood Mononuclear Cell;Plasma;Production;Proteins;prototype;rational design;Recombinants;Recommendation;Resistance;Respirovirus;response;Rift Valley fever virus;Rubulavirus;Sampling;SARS coronavirus;screening;single cell technology;single-cell RNA sequencing;Sorting;Specificity;Specimen;Structure;Surface;surveillance study;Technology;Therapeutic;Therapeutic Agents;Therapeutic antibodies;Therapeutic Monoclonal Antibodies;Therapeutic Uses;Toscana virus;Transgenic Organisms;Uganda;Universities;Vaccinated;Vaccination;vaccination strategy;vaccine candidate;Vaccine Design;vaccine-induced antibodies;Vaccines;Vesicular stomatitis Indiana virus;Viral;Virus;Washington;Work

PROJECT_TITLE: Core D:  Antibody Core


PI_NAMEs: MCELROY, ANITA K (contact)

PROJECT_TERMS: adaptive immunity;Animals;Antibodies;Antibody Response;antigen binding;antigen test;Antigens;Benchmarking;Biological Assay;Chiroptera;cytokine;data integration;Data Set;Elasticity;emerging virus;Encapsulated;enzyme linked immunospot assay;explainable machine learning;Family;Flow Cytometry;Glycoproteins;Goals;heuristics;Human;Humoral Immunities;Immune;Immune response;Immunity;immunogenicity;Immunologics;Immunology procedure;Infection;Intervention;Machine Learning;machine learning algorithm;machine learning prediction;Measurable;Measurement;Monoclonal Antibodies;multimodality;Mumps;neutralizing antibody;novel;novel virus;Oropouche virus;pandemic potential;pathogen;Peptides;Peripheral Blood Mononuclear Cell;Plasma;pre-clinical;Pre-Clinical Model;prototype;random forest;response;Rodent;Rodent Model;Sampling;Series;Serum;Splenocyte;Stains;Standardization;success;T-Lymphocyte;Therapeutic antibodies;Therapeutic Monoclonal Antibodies;Vaccinated;Vaccination;vaccine-induced antibodies;Vaccines;Viral;Virus

PROJECT_TITLE: Core E:  Immunogenicity and Immune Correlates Core


PI_NAMEs: MOSCONA, ANNE  (contact)

PROJECT_TERMS: Address;Affinity;Antibodies;Antigen Presentation;Antigens;B-Lymphocytes;Back;Binding;Binding Proteins;Blocking Antibodies;Cell fusion;Cell membrane;Cell Separation;Chimeric Proteins;Complex;Cotton Rats;Cryoelectron Microscopy;design;efficacy evaluation;efficacy testing;electron tomography;env Gene Products;Epitopes;Family member;Genetic;Glycoproteins;Hemagglutinin;HN Protein;Human;human monoclonal antibodies;Ideal 1;Immune system;Immunity;immunogenicity;In Vitro;in vivo;Knowledge;Learning;Mediating;member;Membrane Fusion;Membrane Glycoproteins;Membrane Proteins;Messenger RNA;Modeling;Monoclonal Antibodies;Mus;Neuraminidase;Para-Influenza Virus Type 1;Para-Influenza Virus Type 3;Paramyxovirus;Pathway interactions;preclinical development;Process;programs;Protein Subunits;Proteins;prototype;receptor;receptor binding;Resistance;Resolution;Respirovirus;Structure;Structure-Activity Relationship;Surface;Testing;Therapeutic;Therapeutic antibodies;Vaccine Antigen;vaccine candidate;Vaccine Design;vaccine development;vaccine platform;vaccine-induced antibodies;Vaccines;Vesicular stomatitis Indiana virus;Viral;Viral Physiology;Virus

PROJECT_TITLE: Prototype strategies for antibodies and vaccines for respiroviruses


PI_NAMEs: DUPREX, WILLIAM PAUL (contact)

PROJECT_TERMS: 2019-nCoV;Animal Disease Models;Animals;Antibodies;Antibody Response;Antigens;Attenuated Vaccines;B-Lymphocytes;Binding;Biochemical;Biological Assay;Biological Models;Biology;Cell fusion;Cells;Chiroptera;Collaborations;Complex;Coronavirus;Cotton Rats;COVID-19 vaccine;Cryo-electron tomography;Data;Decision Making;design;Development;Disease;Educational workshop;Epitope Mapping;Epitopes;Evaluation;Genetic;Glycoproteins;Goals;Head;Human;human monoclonal antibodies;humanized mouse;Humoral Immunities;Immunity;Immunization;immunogenicity;Immunoglobulins;In Vitro;in vivo;in vivo Model;Individual;Industrialization;Industry;Infection;iterative design;Knowledge;Lead;Length;Licensing;lipid nanoparticle;Location;Messenger RNA;Modeling;Molecular;Monoclonal Antibodies;Mumps;Mumps virus;Mus;National Institute of Allergy and Infectious Disease;neutralizing monoclonal antibodies;next generation;pandemic disease;pandemic potential;pandemic preparedness;pandemic response;Paramyxovirus;pathogen;pathogen spillover;Pathway interactions;pre-pandemic;protective efficacy;Proteins;prototype;Reagent;receptor;Regimen;Resistance;resistance mutation;respiratory pathogen;Respiratory System;Respirovirus;Rubulavirus;Series;Species Specificity;Structure;Structure-Activity Relationship;sugar;synergism;Test Result;Testing;Therapeutic antibodies;Transgenic Organisms;Translating;Translations;transmission process;Vaccinated;vaccination strategy;Vaccine Antigen;vaccine candidate;vaccine development;vaccine platform;vaccine strategy;vaccine-induced antibodies;Vaccines;Variola major virus;Virion;Virus;Work;Zoonoses

PROJECT_TITLE: Prototype strategy for vaccines and antibodies to rubulaviruses


PROJECT_TERMS: Acceleration;Animal Model;Animals;Antibodies;Antigens;Appearance;Biochemical;Biological Assay;Blocking Antibodies;Chimeric Proteins;Complex;Core Protein;Decision Making;design;Development;Disease;disease model;Encephalitis;Engineering;Ensure;env Gene Products;Enzyme-Linked Immunosorbent Assay;Family member;Genetic;genome-wide;Goals;group competition;Human;Immune response;Immune system;immunogenicity;In Vitro;in vivo;in vivo Model;Infection;Knowledge;La Crosse virus;lipid nanoparticle;loss of function;Low Density Lipoprotein Receptor;Measures;Mediating;member;Membrane Fusion;Membrane Proteins;Messenger RNA;Monitor;Monoclonal Antibodies;mouse model;mRNA lipid nano particle vaccine;neutralizing antibody;novel;Open Reading Frames;Oropouche virus;Orthobunyavirus;particle;pathogen;Peripheral Blood Mononuclear Cell;Persons;Polymerase;Polyproteins;prophylactic;protective efficacy;Protein Biosynthesis;Protein Subunits;Proteins;Proteolytic Processing;prototype;receptor;receptor binding;Recording of previous events;Reporting;Resistance;Site;Structure;synergism;targeted treatment;Testing;Therapeutic;Therapeutic antibodies;Therapeutic Monoclonal Antibodies;tool;vaccine development;vaccine platform;vaccine strategy;vaccine-induced antibodies;Vaccines;vector;vector vaccine;Vesicular stomatitis Indiana virus;Viral;Viral Genome;viral resistance;Virion;Virus;Virus Diseases;Virus Replication;Work

PROJECT_TITLE: Prototype strategy for vaccines and antibodies to Peribunyaviridae


PI_NAMEs: HARTMAN, AMY L (contact)

PROJECT_TERMS: Affinity;Africa;Antibodies;Antibody Response;Antigens;Arthropod Vectors;Biochemistry;Biology;Blocking Antibodies;Bunyavirales;Characteristics;Clinical;Common Epitope;comparative efficacy;design;Development;Disease;Distant;Encephalitis;env Gene Products;Epitope Mapping;Epitopes;Event;experience;experimental study;Family;Family member;fetal infection;Fever;Genetic;glycoprotein structure;Glycoproteins;Goals;Human;immunogenicity;in utero;In Vitro;in vivo;Infection;Infection prevention;Knowledge;Maps;medical countermeasure;Messenger RNA;Monoclonal Antibodies;mouse model;Mus;Names;National Institute of Allergy and Infectious Disease;Nervous System Disorder;novel;Outcome;pathogen;pressure;Proteins;prototype;Reagent;receptor;receptor binding;Resistance;Rift Valley fever virus;Saudi Arabia;Severe Fever with Thrombocytopenia Syndrome Virus;Solid;structural biology;Structure;Survivors;synergism;System;Testing;Therapeutic;Therapeutic antibodies;Toscana virus;vaccine development;vaccine platform;vaccine strategy;vaccine-induced antibodies;Vaccines;vaccinology;Vesicular stomatitis Indiana virus;Viral;Viral Hemorrhagic Fevers;viral transmission;Virus;Work

PROJECT_TITLE: Design and development of generalizable countermeasures against prototype Phenuiviruses


ADMINISTERING_IC: VA

IC_NAME: Veterans Affairs

ORG_CITY: INDIANAPOLIS

ORG_NAME: RLR VA MEDICAL CENTER

ORG_STATE: IN

PHR: Social isolation is a negative social determinant of health (SDoH) that affects 1-in-5 adults in the U.S. and 43% of Veterans. Social isolation is estimated to cost the nation $6.7 billion annually in federal healthcare spending. Yet, social isolation has rarely been the direct focus of healthcare interventions. The proposed project is a randomized controlled trial that seeks to test the effectiveness of the Increasing Veterans’ Social Engagement and Connectedness (CONNECTED) intervention on social isolation among diverse Veteran groups in primary care clinics. CONNECTED involves three key services delivered by peers via telehealth through individual and group sessions over 8 weeks: 1) peer support, which includes person-centered assessment for social isolation, 2) psychosocial interventions to address social isolation, and 3) navigation (i.e., connecting Veterans to social resources). Findings from this study will contribute to the VA’s efforts to address SDoH among Veterans and to provide high quality, person-centered, and equitable care to all Veterans.

PI_NAMEs: ELIACIN, JOHANNE  (contact)

PROJECT_TERMS: acceptability and feasibility;Address;Adoption;Adult;Advocacy;Affect;Age;Anxiety;attentional control;Automobile Driving;Awareness;Cardiovascular Diseases;cardiovascular disorder risk;Caring;Cessation of life;Clinical Trials;Communities;comparison control;Control Groups;cost;COVID-19 pandemic;Data;Dementia;Development;effective intervention;effectiveness testing;effectiveness/implementation design;Elements;Equity;equity, diversity, and inclusion;ethnic diversity;Ethnic Origin;Evaluation;evidence base;Expectancy;experience;Feeling suicidal;formative assessment;Frequencies;future implementation;gender diverse;Goals;Health;health care service utilization;health related quality of life;Health Services;Health system;Healthcare;Healthcare Systems;Hospitalization;Hybrids;Impaired cognition;implementation evaluation;implementation process;implementation strategy;improved;Individual;innovation;Intervention;Intervention Studies;Interview;K-Series Research Career Programs;Linear Models;Lived experience;Loneliness;Manuals;Measures;Mental Depression;Mental disorders;Mental Health;Methodology;military veteran;Modeling;novel;Outcome;Participant;patient navigation;peer;peer support;person centered;Personal Satisfaction;Policies;Population;population health;Population Heterogeneity;premature;Prevalence;primary care clinic;primary endpoint;programs;Provider;psychosocial;Public Health;Race;racial diversity;Randomized Controlled Clinical Trials;Randomized, Controlled Trials;Recording of previous events;Research;Research Assistant;Resources;Risk;Risk Factors;Sampling;Services;social;social attachment;social contact;social engagement;social health determinants;Social isolation;Social Network;Social support;Source;Specialist;Structure;Subgroup;suicidal;suicidal risk;Supportive care;Surgeon;Surveys;telehealth;Testing;Training;trial comparing;Veterans;Veterans Health Administration;Visit;Work;World Health Organization

PROJECT_TITLE: Increasing Veterans' Social Engagement and Connectedness (CONNECTED)

STUDY_SECTION_NAME: HSR-2 Behavioral, Social, and Cultural Determinants of Health and Care[HSR2]


NIH_SPENDING_CATS: Autoimmune Disease;Clinical Research;Crohn's Disease;Digestive Diseases;Inflammatory Bowel Disease;Microbiome;Nutrition

ORG_CITY: Aurora

ORG_DEPT: PEDIATRICS

ORG_NAME: UNIVERSITY OF COLORADO DENVER

ORG_STATE: CO

PHR: Project Narrative Inflammatory bowel disease is a disease notable for intestinal energetic stress, such as down regulation of the machinery required to use creatine. We will evaluate the impact of creatine transporter loss on the mucous producing cells of the intestines and the impact that loss has on the bacteria and energetic factors in the intestine. This is significant because disruption of energy, bacteria and barrier function all contribute to inflammatory bowel disease activity and understanding their interactions could provide more targeted therapeutic targets.

PI_NAMEs: HALL, CAROLINE H (contact)

PROGRAM_OFFICER_NAME: SASLOWSKY, DAVID E

PROJECT_TERMS: Adult;Antigens;Area;Bacteria;Biology;Biopsy Specimen;Buffers;Cell Count;Cell Differentiation process;Cell Physiology;cell type;Cells;Child;Clinical;Clinical Trials;Colitis;Colon;Complex;Creatine;creatine transporter;Crohn's disease;Development;differential expression;Disease;Disease susceptibility;Down-Regulation;Environment;Environmental Risk Factor;Epithelial Cells;Epithelium;Evaluation;experience;experimental study;Functional disorder;Gastroenterology;Gastrointestinal tract structure;Glycolysis;Goals;Goblet Cells;Health;Immune system;Immunosuppression;improved;In Vitro;Incidence;Infection;Infectious Agent;Inflammation;Inflammatory;Inflammatory Bowel Diseases;Intervention;intestinal epithelium;Intestinal Mucosa;Intestines;Maintenance;Malignant Neoplasms;Mediating;Metabolic;Metabolic stress;Metabolism;microbial;microbiome;microbiome alteration;Minority;Modeling;Morbidity - disease rate;mortality;Mucous body substance;Mucous Membrane;murine colitis;Mus;Nature;notch protein;novel;Organoids;Pathway interactions;Patient Care;Patients;Population;Predisposition;prevent;protein expression;Qualifying;Ras Signaling Pathway;Regulation;Reporting;Risk;Role;salmonella colitis;side effect;Signal Pathway;single-cell RNA sequencing;stem cells;Stress;targeted treatment;Therapeutic;Therapeutic Intervention;therapeutic target;Thick;Training;trinitrobenzene sulfonic acid induced colitis;Ulcerative Colitis;United States;Work;wound healing

PROJECT_TITLE: Determining the role of the creatine pathway regulation of intestinal goblet cell development in colitis

STUDY_SECTION_NAME: Fellowships in Digestive Diseases and Nutrition[DDK-F]


NIH_SPENDING_CATS: Aging;Behavioral and Social Science;Breast Cancer;Cancer;Diabetes;Estrogen;Nutrition;Obesity;Prevention;Women's Health Research

ORG_CITY: SAN DIEGO

ORG_NAME: VETERANS MEDICAL RESEARCH FDN/SAN DIEGO

PHR: Aging and obesity are strong risk factors for breast cancer in women because as ovarian estrogen declines, women have less protection from the harmful effects of obesity, which causes inflammation and increases insulin levels. These harmful effects can be reversed by weight loss but this is often not sustainable. We have shown that a novel dietary intervention using time-restricted feeding of a western-style, high-fat diet prevents the effect of obesity to drive breast cancer in mice; the proposed studies will investigate whether this intervention has a beneficial effect during hormonal or chemotherapy.

PI_NAMEs: WEBSTER, NICHOLAS J (contact)

PROGRAM_OFFICER_NAME: EMENAKER, NANCY J

PROJECT_TERMS: Age;Age Years;Aging;animal data;Anti-estrogen Therapy;Behavior Therapy;blood glucose regulation;Body Weight decreased;Breast Cancer cell line;Breast Cancer Model;Breast Cancer Patient;Breast Cancer Prevention;Breast Cancer Risk Factor;Breast Cancer therapy;cancer initiation;cancer risk;cancer survival;Carcinogens;Central obesity;chemotherapy;circadian pacemaker;Circadian Rhythms;Clinical;Colon Carcinoma;combat;comorbidity;Cues;Data;Diagnosis;diet and exercise;dietary;Dietary Intervention;Distant Metastasis;Eating;epidemiologic data;Epidemiology;epidemiology study;ERBB2 gene;Estrogen decline;Estrogen receptor positive;experimental study;Exposure to;Fasting;Goals;Growth;Health Benefit;High Fat Diet;hormone therapy;Human;Hyperinsulinism;improved;Incidence;individual response;Inflammation;inflammatory breast cancer;Insulin;Insulin Resistance;insulin signaling;Intake;Intervention;Lead;Liver;Malignant Breast Neoplasm;Malignant neoplasm of liver;Malignant Neoplasms;Mammary Neoplasms;Metabolic;mortality;mouse model;Mus;Neoplasm Metastasis;neoplastic cell;novel;Nutrient;obese person;Obesity;Obesity Epidemic;Omega-3 Fatty Acids;Oncogenes;Outcome;Ovarian;patient derived xenograft model;Patients;Population;Postmenopause;pre-clinical;Pre-Clinical Model;preclinical study;Premenopause;prevent;progesterone receptor positive;Randomized Controlled Clinical Trials;Recurrence;reduced food intake;response;Risk;Rodent;Series;Signal Pathway;survivorship;synergism;Testing;Time;time use;Time-restricted feeding;Tissues;treatment response;triple-negative invasive breast carcinoma;tumor;tumor growth;tumor progression;weight loss intervention;Woman;women's treatment

PROJECT_TITLE: The Effect of Time-Restricted Eating on the Efficiency of Chemo- and Hormonal-Therapy in Breast Cancer

STUDY_SECTION_NAME: Special Emphasis Panel[ZCA1 SRB-A (J1)]


ORG_NAME: VA GREATER LOS ANGELES HEALTHCARE SYSTEM

PHR: Prostate cancer is diagnosed in approximately 12,000 American Veterans annually accounting for one third of all cancer diagnoses in American male Veterans. It is the second leading cause of cancer death in American male Veterans, and the number one cause of cancer-specific death amongst non-smoker Veterans. In addition to death, the treatments for prostate cancer have frequent and predictable detrimental impacts on Veterans’ quality of life. This burden is most intensely experienced by Veterans living with metastatic prostate cancer where the backbone of treatment is indefinite medical castration therapy. By leveraging advances in non-hormonal active therapy, our proposal promises to improve treatment efficacy and quality of life for Veterans with lethal prostate cancer. Specifically, comprehensive non-hormonal therapy in the form of targeted radiopharmaceutical therapy combined with metastasis directed precision radiotherapy, followed by physiologic restoration of testosterone will improve efficacy of therapy while simultaneously improving quality of life.

PI_NAMEs: JOHNSON, RUDOLPH C;NICKOLS, NICHOLAS GEORGE (contact);RETTIG, MATTHEW B

PROJECT_TERMS: abiraterone;Accounting;Active Sites;American;Androgen Antagonists;Androgen Receptor;arm;Beta Particle;Biological Markers;Biology;cancer diagnosis;Cancer Etiology;Castration;Cells;Cessation of life;Clinical;Clinical Trials;Combined Modality Therapy;comorbidity;Data;Diagnosis;Disease;Disease Resistance;DNA Sequence Alteration;docetaxel;Dose;enzalutamide;experience;experimental arm;fluorodeoxyglucose positron emission tomography;FOLH1 gene;Generations;Genomics;Hormonal;Image;improved;Ionizing radiation;male;Malignant neoplasm of prostate;Measures;Medical Castration;Metastatic Prostate Cancer;Modernization;Neoplasm Metastasis;non-smoker;Outcome;overexpression;palliation;palliative;Patients;PET/CT scan;Phase II Clinical Trials;phase II trial;Physiological;primary endpoint;prognostic value;Progression-Free Survivals;prospective;Prostate Cancer therapy;Provenge;Quality of life;Radiation;Radiation therapy;radioligand;radiological imaging;Radiopharmaceuticals;Radium;Randomized, Controlled Trials;Recurrence;Reporting;restoration;Risk;Safety;secondary endpoint;Sex Functioning;side effect;Site;success;Techniques;Testosterone;testosterone replacement therapy;Therapeutic;Therapeutic Intervention;therapeutic target;Time;tool;Treatment Efficacy;tumor;Vertebral column;Veterans;virtual

PROJECT_TITLE: Phase II Trial of targeted Radiation with no castration for mcrpc (POTENT-C)

STUDY_SECTION_NAME: Special Emphasis Panel[ZRD1 SPLP-Y (01)]